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SCP-1, a potent derivative of acetaminophen, exhibits significantly diminished hepatotoxicity 
and nephrotoxicity relative to acetaminophen and nitrate ester derivatives of acetaminophen. It 
was therefore of interest to explore the development of nitric oxide donor analogs of SCP-1 to 
identify compounds that could have enhanced analgesic and/or antipyretic activity while taking 
advantage of the very low liver and kidney toxicity inherent to SCP-1. In this project, a series of 
nitrate ester analogues of the SCP-1 were prepared as potential nitric oxide donors. The synthesis 
of SCP analogs was achieved by triflic acid catalyzed O-acylation of SCP-1 with chloroalkanoyl 
chlorides followed by nitration with silver nitrate. The chloroesters and corresponding nitrate 
esters were obtained in high yields (>90%). Preliminary hepatotoxicity studies revealed the nitrate 
esters to be well tolerated by human hepatocytes and had little effect on the three cytochrome P450 
enzymes tested (CYP3A4, CYP2E1 and CYP2D6). In addition, the nitrate esters exhibited 
antipyretic activity similar to acetaminophen. 
With the emerging interest in 3,3-diarylazetidines as novel motifs in drug discovery programs, 
an easy, efficient, scalable synthetic method that could accommodate the introduction of both 
electron-rich and electron-deficient aryl groups for preparation of diversely substituted 3,3-
diarylazetidines would be valuable to medicinal chemists. In this second project, a versatile 
synthesis of 3,3-diaryl azetidines from N-Boc-3-aryl-3-azetidinols using Friedel-Crafts arylation 
conditions with AlCl3 is described. A series of substituted diaryl azetidines were readily prepared 
and isolated as the oxalate salts in high yield and high purity.  The 3,3-diaryl azetidine oxalates 
were then easily converted into N-alkyl and N-acyl analogues in high overall yields (>85%). 
xix 
 
In the last project, A general synthesis of pyruvate esters was developed. Using this method, a 
series of alkyl pyruvate esters were synthesized in moderate to high yields (56-93%). This was 
achieved in four steps starting from the readily available triethyl-2-phosphonopropionate which 
was converted to the alkene ethyl 2,3-dimethyl-2-butenoate using Horner-Wadsworth-Emmons 
reaction. The ethyl ester was hydrolyzed to the corresponding carboxylic acid after which a series 
of esters were prepared using Steglich esterification. The esters were then converted to their 
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Synthesis, hepatotoxic evaluation and antipyretic activity of nitrate ester analogs 





SCP-1 is a potent saccharin derivative of acetaminophen which is used for acute and chronic 
pain. SCP-1 demonstrated an analgesic profile similar that to that of acetaminophen. However, 
SCP-1 exhibited significantly diminished hepatotoxicity and nephrotoxicity relative to 
acetaminophen and nitrate ester derivatives of acetaminophen. It was therefore of interest to 
explore the development of nitric oxide donor analogs of SCP-1 to identify compounds that could 
have enhanced analgesic and/or antipyretic activity while taking advantage of the very low liver 
and kidney toxicity inherent to SCP-1. In this project, a series of nitrate ester analogues of the 
SCP-1 were prepared as potential nitric oxide donors. The synthesis of SCP analogs was achieved 
by triflic acid catalyzed O-acylation of SCP-1 with chloroalkanoyl chlorides followed by nitration 
with silver nitrate. The chloroesters and corresponding nitrate esters were obtained in high yields 
(>90%). Preliminary hepatotoxicity studies revealed the nitrate esters to be well tolerated by 
human hepatocytes and had little effect on the three cytochrome P450 enzymes tested (CYP3A4, 












1.1 Nitric oxide donors 
Nitric oxide donors (NO donors) are compounds that under physiological conditions release 
nitric oxide (NO). The most popular NO donor is Glyceryl trinitrate (GTN) or nitroglycerin. 
Although the use of GTN for medicinal purposes dates back to more than 150 years, little had 
been revealed about its physiological mechanism of action before the 1980s [1]. GTN was first 
discovered in 1847 by Ascanio Sobrero in Turin, following work with Theophile‐Jules Pelouze. 
Alfred Nobel joined Pelouze in 1851 and recognized the potential of GTN. The invention realized 
by Alfred Nobel in 1863 paved the way for controlled detonation of GTN. Therefore, when 
Nobel’s physician recommended GTN as treatment of his angina pectoris, Nobel wrote “Isn’t it 
the irony of fate that I have been prescribed nitroglycerin to be taken internally! They called it 
Trinitrin, so as not to scare the chemist and the public” [2]. There would not be any irony for 
Nobel if he knew that it was nitric oxide (NO), released from GTN in vivo, that helped to relieve 
his angina.  During the mid‐19th century, scientists in Britain took an interest in the newly 
discovered amyl nitrite, and recognized it as a powerful vasodilator. Lauder Brunton, the father of 
modern pharmacology, used the compound to relieve angina in 1867, noting the pharmacological 
resistance to repeated doses. In 1977, Ferid Murad discovered the release of NO from GTN and 
its action on vascular smooth muscle [3]. In 1980, Robert Furchgott and John Zawadski 
recognized the importance of the endothelium in acetylcholine‐induced vasorelaxation and in 
1987, Louis Ignarro and Salvador Moncada identified NO as the endothelial‐derived relaxing 
factor (EDRF) [4] [5]. The surprising and exciting discovery of the multiple roles that NO plays 
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in physiological and pathophysiological functions in humans earned Furchgott, Ignarro, and 
Murad the Nobel Prize in 1998. 
1.2 Organic nitrates 
NO is a colorless gas and may react with a variety of atoms and radicals. For example, it may 
react readily with O2 to give nitrogen dioxide (NO2) [6]; the reaction of NO with superoxide anion 
generates peroxynitrite (ONOO-), an oxidative species that is responsible for certain types of NO-
mediated toxicity in vivo [7]. Due to the instability and inconvenient handling of aqueous solutions 
of authentic NO, there is an increasing interest in using compounds capable of generating NO in 
situ, i.e., NO donors. Organic nitrates, such as GTN (1), may be the most well-known and the 
oldest class of NO donors. Some of the other organic nitrates include pentaerythrityl tetranitrate 
(PETN, 2), isosorbide dinitrate (ISDN, 3), isosorbide 5-mononitrate (ISMO, 4), and nicorandil (5) 
[2]. 
 




Organic nitrates can be readily prepared from the esterification of corresponding alcohols or 
the substitution between reactive alkyl halides and AgNO3 (Scheme 1) [8]. They are sparingly 
soluble in water and are generally stable in neutral or weakly acidic aqueous solutions. Under 
strong alkaline conditions, they are susceptible to hydrolysis to give alcohol and nitrate (SN
2 
substitution), -elimination to give an alkene, and -H elimination to give aldehyde and nitrate 
(Scheme 2) [9] [10]. 
 
 
Scheme 1. Synthesis of organic nitrates 
 
 
Scheme 2. Alkaline hydrolysis of nitrate esters 
The NO release from organic nitrates requires enzymatic or non-enzymatic bioactivation. 
Although the biochemical process of NO release from GTN has not been fully defined, it is likely 
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that multiple intracellular and extracellular pathways contribute to NO formation from these 
compounds in vivo [11]. 
 
Fig. 2. Biotransformation of organic nitrate esters 
It has been suggested that cellular thiols are involved in nonenzymatic formation of NO from 
GTN [12] [13]. However, since the degradation of GTN by thiols is very slow at room 
temperature, it appears that the release of NO from reasonable concentrations of GTN and thiols 
almost certainly involves an enzymatic process [14]. 
1.3 Biological applications of NO donors 
Organic nitrates have long been used to relieve angina pectoris; a disease state caused by 
constriction of heart arteries. In fact, GTN has a relaxant effect on all types of vessels. Coronary 
arteries have been found to be more sensitive to GTN than peripheral arteries. GTN has also been 
used as treatment of acute myocardial infarction [15], congestive heart failure [16], as well as 
blood pressure control. In addition to relaxation of vascular smooth vessels, GTN is successful in 
the treatment of children with anal fissures when administered as an ointment [17] and as an 
alternative to sildenalfil (Viagra) for the treatment of erectile dysfunction [18]. Rectal 
administration of 1 has been claimed as treatment for prophylaxis of inflammatory bowel disorders 
[19]. It has been suggested that 3 can be used as a long-term transdermal therapy in preeclamptic 
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women to avoid maternal hypertension and fetal distress [20]. It was recently reported that organic 
nitrates eventually inhibited the proliferation of smooth muscle cells (SMC), which was associated 
with the pathogenesis and progression of atherosclerosis [21] [22] [23]. 
The role in tumor growth arrest by NO was initially suggested by the observation that murine 
activated macrophages synthesized nitrite and nitrate leading to cytotoxicity of tumor cells and 
bacteria [24] [25] [26]. This anti-tumor activity of NO first opened the door to identifying a 
function of NO as a potential oncologic agent. In general, it has been suggested that at high 
concentrations NO may have an anti-neoplastic function whereas at low levels it can be pro-
angiogenic and pro-tumor formation [27]. NO at high concentrations causes programmed cell 
death and at low levels protects the cell from apoptosis, which has been suggested to be the result 
of a dual role of the transformation-related protein 53 (p53) [28]. In this phenomenon, low 
concentrations of NO may induce p53 alterations or mutations, which cause tumor cell resistance; 
however, at high concentrations, the DNA damage induced by NO increases wild-type p53 leading 
to programmed cell death [29] [30]. 
1.4 NO-drug hybrids 
The specific characteristics of NO in vasodilatation and a potential role as an anti-neoplastic 
agent on its own and has led to the development of new hybrid drugs with synergistic activities 
and minimal side effects that may be caused by either drug alone. For instance, a recent study by 
Chan et al. showed that the regular use of the non-steroidal anti-inflammatory drug (NASAID), 
aspirin, reduced the risk of colorectal cancers in tumors that over-expressed COX-2 [31]. 
However, in tumors that showed weak or absent expression of COX-2 the chemo preventive 
effects were minimal; while the potential side effects of aspirin, including peptic ulcer disease, 
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were retained in both cohorts. Since established drugs that inhibit carcinogenesis are COX-2 
inhibitors, a logical hybrid is one that combines nitric oxide and the non-steroidal anti-
inflammatory drugs (NO-NSAIDs). The NO-aspirin analog 6 (Fig. 3) developed by Thatcher et 
al., demonstrated no toxicity when given to human subjects while maintaining COX-1 and 
antiplatelet activity [32].  
NO-NSAIDs are composed of typical non-steroidal anti-inflammatory drugs such as aspirin, 
salicylic acid, indomethacin, ibuprofen or sulindac to which an NO-releasing moiety has been 
attached via a covalent bond that is cleaved by non-specific esterase activity. It is the bond between 
the linker and the NSAID that is cleaved by enzymatic activity. Upon cleavage, the NSAID exerts 
its COX-inhibitory functions and the generated NO acts in synergy to potentiate the actions of 
both compounds [32]. 
 
In 2000, Swayeh et al. reported that nitric oxide (NO) releasing derivatives of NSAID exhibit 
greater anti-inflammatory, antinociceptive and anti-thrombotic activity than the parent NSAID 
[33]. With this in mind, they synthesized NO releasing derivative of acetaminophen. This nitrate 
ester of acetaminophen (NO-APAP, 7) has been reported to exhibit enhanced anti-nociceptive and 
anti-inflammatory activity relative to APAP over similar dose ranges. More recently, NO-APAP 
has been shown to have a reduced hepatotoxicity in human hepatocytes than APAP. Nitric oxide 
release from NO-APAP is a metabolic and not a spontaneous process. Furthermore, this process 
causes the production of discrete amounts of NO that do not interfere with blood pressure 




Fig. 3. Structures of some well-known NO-NSAIDS 
1.5 Acetaminophen toxicity 
The most commonly employed method of managing pain involves the systemic administration of 
analgesics. Traditionally, analgesics fall into two broad categories: (1) simple, non-narcotic 
analgesics, such as aspirin, which appear to work by inhibition of prostaglandin synthetase [34], 
and (2) narcotic analgesics, which appear to work through interaction with the 
endorphin/enkephalin receptor system of the central nervous system [35]. Narcotic analgesics, can 
be further divided into two groups, the opioids and non-opioids. The opioid analgesics include 
among others the phenanthrene alkaloids of opium, comprising morphine, codeine, and thebaine. 
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The drugs that comprise the group known as the non-opioid analgesics include: (1) N-methyl-D-
aspartate (NMDA) receptor antagonists, such as dextromethorphan and ketamine [36]; (2) alpha2 
adrenoreceptor agonists, such as clonidine, metomidine, detomidine, dexmetomidine, 
dexmedetomidine and xylazine, that reduce the release of norepinephrine; (3) other agents, such 
as tramadol, often mistakenly referred to as an opioid, that produce analgesia by their inhibitory 
actions on monoamine re-uptake rather than by agonist effect; (4) non-steroidal anti-inflammatory 
drugs such as aspirin, ibuprofen and other drugs that inhibit cyclooxygenase enzymes [37] and (5) 
mixed agonist-antagonist analgesics such as buprenorphine, dezocine, nalbuphine. Opioid and 
non-opioid analgesics may cause a variety of side effects including sedation, constipation, 
hypotension, nausea, vomiting, elevation of cerebrospinal fluid pressure, respiratory depression, 
physical dependence and tolerance [38]. Therefore, there is a serious need to develop 
combinations of drugs that supplement the activity of the opioid and non-opioid analgesics, which 
allows the use of smaller doses of the opioid and non-opioid analgesics [39]. 
Analgesics such as acetaminophen and other NSAID type drugs have been used for some time 
for the treatment of pain and/or as antipyretics. However, its high toxicity is the foremost cause 
of acute liver failure in the western world [40] [41] [42]. In therapeutic use, it is metabolized by 
hepatic cytochrome P450 enzyme CYP2E1 to N-acetyl-p-benzoquinone imine (NAPQI), which 
is then immediately conjugated with glutathione (GSH) to form a non-toxic mercapturic acid 
conjugate which is excreted in urine [43] [44]. In the case of an overdose, glutathione stores are 
overwhelmed and free NAPQI is able to combine with hepatic macromolecules to produce 





Fig. 4. Mechanism of acetaminophen toxicity 
1.6 A series of N-acylated-4-hydroxyphenylamine derivatives (SCP series) 
In 1996, Bazan et al. synthesized a series of N-acylated-4-hydroxyphenylamine derivatives, 
linked via an alkyl bridge to the nitrogen atom of a saccharin molecule. This series of compounds 
was named the “SCP series” (Fig. 5) [45]. The SCP series are non-narcotic analgesics that are free 
from antipyretic activity and have little hepatotoxic effect. The compounds in this series do not 
produce the metabolite (NAPQI) that is responsible for acetaminophen toxicity and they do not 
reduce fever. As a result, they are more useful than acetaminophen and other non-narcotic 
analgesics in the treatment of chronic pain and in situations in which controlling fever is 
contraindicated, such as after surgery, where fever control can mask infection. Moreover, unlike 
conventional non-narcotic analgesics, such as aspirin or ibuprofen, the SCP series does not 




Fig. 5. SCP series, n = 1 to 5 
One of them, SCP-1 (n=1) showed analgesic activity equivalent to acetaminophen but, in 
contrast to the latter, possesses much lower toxicity. Furthermore, SCP-1 (12) had the great 
advantage of not showing antipyretic activity, since antipyresis can mask the presence of latent 
infections during the post-operative period. It was found to rapidly hydrolyze in vivo to give SCP-
123 (13) which is equipotent on a molar basis with 12. 
 
 
Fig. 6. Structures of SCP-1 and SCP-123 
1.7 Synthesis of SCP-1 and SCP-123 
In 1996, Bazan et al. developed the synthesis of 12 which was prepared by the means of two 
synthetic routes [45]. In route 1 (Scheme 3), 2-chloro-N-(4-hydroxyphenyl)acetamide (14) was 
reacted with the sodium salt of saccharin (15) in dimethylformamide (DMF). The mixture was 
heated at reflux for 3 hours. At the end of this time, the NaCl formed was filtered off and the 
13 
 
filtrate was evaporated under reduced pressure. The resulting oil was crystallized in 200 mL of n-
hexane/acetone (1:1) and the product thereby obtained was recrystallized in ethanol which yields 
12 as a white crystalline solid in 86% yield. 
 
Scheme 3. Synthesis of 12 (Route 1) 
Alternatively, in route 2 (Scheme 4), the acid 16 was reacted with 4-aminophenol (17) in the 
presence of a coupling agent such as dicyclohexylcarbodiimide (DCC). The reaction was carried 
out in anhydrous methylene chloride (DCM). The reaction was stirred at room temperature for 2 
hours. The resulting solid was filtered off and recrystallized in ethanol/water (1:1) to give 12 in 
70 % yield. 
 
Scheme 4. Synthesis of 12 (Route 2) 
In 2009, Miao et al. developed the first multigram synthesis of SCP-123 and its sodium salt 
[46]. Two synthetic routes have been established for its synthesis with two routes differing 
primarily in the sequence in which the saccharin moiety is added to the acetyl unit. In Route A 
(Scheme 5), the saccharin moiety (15) is added in the last step to the 2-chloroacetamide 
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intermediate 18 that is generated from 4-aminophenol (17, 150g) and 2-chloroacetyl chloride (19, 
155 g) in a solution of acetic acid and sodium acetate. The reaction is kept cold and stirred at ≤ 5 
℃. The intermediate 18 precipitates out as a white solid which is then filtered with distilled water 
to give 18 in a 70% yield. 
 
Scheme 5. Synthesis of SCP-1 (Route A) 
Chloroacetamide (18, 326 g) is then added to the sodium salt of saccharin (15, 433 g) in 
the presence of a catalytic amount of sodium iodide (NaI). The reaction is heated at reflux in DMF 
for 2 hours. Ice-water is added to the reaction mixture until no more precipitate forms. The sticky 
white precipitate is then recrystallized in 50% ethanol-water to yield SCP-1 (12) in 72% yield. 
Alternatively, in Route B (Scheme 6), the intermediate acetic acid 16 is formed initially from 
sodium saccharin (15) and bromoacetic acid (20). The acid 16 is then coupled with 17 to give 12 
also via a two-step process. Route A was deemed to be of greater merit due the low cost of the 
commercially available starting materials and also because both the intermediate 18 and 12 could 
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be obtained in a state of high purity (>95%) by precipitation or recrystallization. Alternatively, 
Route B is potentially limited by the hygroscopic intermediate acid 16, which is difficult to handle, 
as well the multiple recrystallizations of 12 that are necessary to remove DCC present as a 
byproduct from the coupling reaction. 
 
 
Scheme 6. Synthesis of SCP-1 (Route B) 
 
The hydrolysis of 12 was readily achieved with NaOH solution followed by treatment with 2 
N HCl (Scheme 7). This afforded the corresponding acid 21 (SCP-123) in 93% yield.  The 
hydrolysis step was found to be sensitive to the concentration of the saccharin derivative 12 in the 
basic solution. If the reaction mixture was not sufficiently dilute, the formation of side product 22, 





Scheme 7. Synthesis of SCP-123 
 
An optimized concentration of 12 in 0.5 N NaOH was determined to be 0.25 M. At this 




Fig. 7. Byproduct 22 
1.8 Design strategy for NO-SCP-1 hybrids 
The goal of this project was to synthesize a series of NO-donor analogs of SCP-1 which could 
have similar analgesic properties to SCP-1 but also show reduced hepatotoxicity. Since, 
previously synthesized NO-drugs typically had a linker molecule that attached the NO moiety to 
the parent NSAID, similar design was incorporated in the synthesis of NO-SCP-1. Comparable to 
NO-acetaminophen, it was decided that that linker molecule would be an alkyl chain attached to 




Fig. 8. NO-SCP-1 analogs; n = 1-4 
A retrosynthetic route for the synthesis of the NO-SCP-1 analogs is outlined in Scheme 8. The 
synthesis would start from the readily available SCP-1. The linker alkyl chain would be attached 
to the phenolic OH via O-acylation using various chloroalkanoyl chlorides. The chloro group 
would then be substituted with a nitrate (-ONO2) group using a simple substitution reaction. 
 
 






1.9 Hydrophobicity in drug design 
Hydrophobicity is most commonly understood as the tendency of non-polar molecules to form 
aggregates in order to reduce their surface of contact with polar molecules such as water [47]. A 
drug’s solubility in water plays a significant role in its design and discovery since the cells in our 
bodies contain about 65% water. In living matter, water acts as an inert solvent, a dispersing 
medium for colloidal solutions and as a nucleophilic reagent in numerous biological reactions. 
Furthermore, hydrogen bonding and hydrophobic interactions in water influence the 
conformations of biological macromolecules, which in turn affects their biological behavior. It 
also makes drug toxicity testing and bioavailability evaluation as well as clinical application 
easier. This means that there is usually a need to design a reasonable degree of water solubility 
into the structure of a new drug early in the development of that drug [48]. 
Oral ingestion is the most commonly employed route of drug delivery due to its ease of 
administration. However, the major challenge with the design of oral dosage forms lies with their 
poor bioavailability. The most frequent causes of this poor bioavailability are attributed to poor 
solubility and low permeability. Drugs administered orally have to dissolve in the aqueous gastric 
fluid before they can be absorbed and transported to their site of action. Drugs that are sparingly 
soluble in water will be deposited before they reach their site of action. This can clog up blood 
vessels and damage organs. Water solubility also affects the transport of drugs through membranes 
such as the blood-brain barrier. The water solubility of an organic compounds depends of the 
number and nature of polar groups in the structure. In general, higher the number of polar groups, 
the more water soluble the compound. However, if a drug is too water soluble, it will not be readily 




1.9.1 Design of water-soluble analogs of SCP-1 
One of the major drawbacks of SCP-1 is its low water solubility. Therefore, there was a need 
to develop analogs of SCP-1 with increased water solubility. One of the methods to increase water 
solubility was to attach a polar group to the phenolic moiety such as a glucose molecule. Addition 
of a carbohydrate molecule to the structure of SCP-1 will not only increase its water solubility but 
also potentially reduce toxicity [50]. Small molecule drugs, no matter how heavily glycosylated, 
will always have the potential to pass into the kidneys, through glomerular filtration, and be 
rapidly cleared.  
Alternatively, the water-solubility of SCP-1 could be increased by hydrolyzing the saccharin 
ring. This can be achieved by synthesizing an array of open ring esters or amides. Amides would 
be preferred since they are more stable and water-soluble compared to esters. 
 
 




RESULTS AND DISCUSSION 
1.10 Nitrate ester analogs of SCP-1 (NO-SCP-1) 
1.10.1 Synthesis of chloroalkanoyl ester analogs of SCP-1 
As illustrated in Scheme 9, the synthesis of the chloroalkanoyl ester analogs of SCP-1 was 
achieved by the O-acylation of the phenolic OH of 12. Complete O-acylation of 22a, 22b, 22c and 
22d was achieved using 2% TfOH/acetonitrile solution [51].  It was observed that lower 
concentrations of TfOH led to incomplete conversion while higher concentrations of TfOH 
afforded intractable mixtures.  
The O-acylation must be carried out in an inert atmosphere and the acid chloride should be 
added dropwise or in small aliquots. Adding the acid chloride all at once resulted in the formation 
of the C-acylated product. This was observed when 3 equivalents of 4-chlorobutyryl chloride was 
added to SCP-1. Addition of acid chloride all at once, led to the formation of a mixture of the 
desired O-acylated product 23c and the C-acylated product 22.  
 







Fig. 11. 1H NMR of 22 
The structure of 22 was confirmed using 1H NMR (Fig. 11). The NMR showed a peak at 12.19 
ppm which corresponded to the phenolic OH of 22. The peak for the phenolic OH of SCP-1 
appears at ⁓10.00 ppm. This shift in the OH peak is attributed to the hydrogen bonding between 
the carbonyl oxygen of the acyl group at the ortho position and the hydrogen of the phenolic OH. 
This hydrogen bonding shifts the signal for the OH peak downfield.  
The optimized reactions conditions produced nearly quantitative yields of the corresponding 
O-acylation products (22a-d) with no observable C-acylation of the electron-rich aromatic ring 
via Friedel-Crafts acylation. 





Scheme 9. Synthesis of Chloroalkanoyl esters of SCP-1 
The amount of chloroalkanoyl chloride varied with the length of the carbon chain; the shorter 
alkyl chain required additional molar equivalents of the chloroalkanoyl chlorides as well as longer 
reaction times for complete conversion into the esters 23a and 23b. Both 23a and 23b required 16 
hours for complete O-acylation with 3 equivalents of the corresponding chloroalkanoyl chloride. 
However, esters 23c and 23d were prepared using only 1.5 and 1.1 equivalents of the 
chloroalkanoyl chlorides respectively, with shorter reaction times (1 hour). The isolated yields of 
the chloroesters are reported in Table 1. The structure of the esters 23b and 23c were 



















Time (h) Yield (%)a 
23a 1 3 16 99 
23b 2 3 16 98 
23c 3 1.5 1 99 
23c 4 1.1 1 99 
a Isolated yields 
1.10.2 Synthesis of Nitrate esters of SCP-1 (NO-SCP-1) 
The synthesis of the nitrate esters was attempted by using AgNO3 in acetonitrile (Scheme 10). 
Reactions were set up by varying the number of equivalents of AgNO3 and the reaction time. 
Initially, 1.5 equivalents of AgNO3 was added to 23c and the reaction was heated at reflux for 2 
hours. The reaction was monitored by Thin Layer Chromatography (TLC) and after 2 hours, there 
was no visible product formation. The reaction time was increased to 6 hours with 2 equivalents 
of AgNO3. There was still no product formation by TLC. Reactions were the carried out 3, 4, 6, 
8, 10 and 12 equivalents of AgNO3 with different reaction times (Table 2). 
 




It was concluded that the molecular polarities of the chloroesters and nitrate esters were similar 
and therefore had the same Rf  values on the TLC plate and also exhibited nearly identical 
1H NMR 
spectra (Fig. 13). 13C NMR was found to be extremely valuable for following the reaction 
progression. A distinct signal for the (C-ONO2) carbon at δ 73.3 ppm was used to follow the 
formation of nitrate esters while the (C-Cl) signal at δ 44.9 ppm inherent to the chloroesters 





































Complete conversion of chloroesters to nitrate esters was observed using 12 equivalents of 
AgNO3 with a reaction time of 72 hours. Using fewer equivalents of AgNO3 resulted in mixtures 
of chloroesters and nitrate esters. This was confirmed by obtaining the X-ray crystal structure of 
the product obtained in entry 5 (Table 2). It was observed that the product was a disordered mix 
of the chloroester and the nitrate ester which means atomic sites in a single crystal contained a 
hybrid atom that contained either the chloro or the nitrate atom. Refinement of the population 
parameters yielded 78% chloro and 22% nitrate (Fig. 15). 
 
 









Table 2. Optimization yields for nitrate ester 24b 
Entry Equivalents of AgNO3 Reaction time (h) Percent yield (%) 
1 1.5 2 86a 
2 2 6 90a 
3 3 24 78a 
4 4 48 80a 
5 6 48 86a 
6 8 72 90a 
7 10 72 88a 
8 12 72 80b 
a Mixtures of chloroesters and nitrate esters 
b Isolated yield of nitrate ester 24b 
 
Reactions were then set up using anhydrous CH3CN to see if would further optimize the 
reaction conditions. It was observed that using anhydrous CH3CN, only 2 equivalents of AgNO3 
was required for a full conversion to the nitrate ester 24b and the product was obtained in 96% 
yield. Furthermore, the reaction time was also reduced to 24 hours (Scheme 11). These optimized 
conditions were then used to synthesize nitrate esters 24b to 24d in good yields (>90%). Attempts 
to prepare the nitrate ester 24a were unsuccessful and led to an intractable mixture. However, the 
longer chain derivatives 24b–d were quite stable and no decomposition was observed over a 
period of several months. The structure of the nitrate ester 24b was established by X-ray 




Scheme 11. Synthesis of nitrate esters 24a-d using optimized condition 
 








1.10.3 Biological evaluation of nitrate esters 24b and 24c 
The nitrate esters 24b and 24c were then evaluated for hepatotoxicity. Hepatic GSH 
(Glutathione) levels were measured in human liver cells over a period of 3, 6 and 12 h for nitrate 
esters 24b (MD-38) and 24c (MD-39). At 500 μM, both 24b (MD-38) and 24c (MD-39) led to 
some GSH depletion as compared to SCP-1 and APAP. However, the level remains constant over 
a period of 12 h and does not deplete any further (Fig. 17). At 1000 μM of 24b (MD-38) and 24c 
(MD-39), GSH levels for both compounds were found to be comparable to SCP-1 and higher than 
that of APAP after a period of 12 h. Therefore, both 24b (MD-38) and 24c (MD-39) were well 
tolerated by the human hepatocytes and were generally less toxic than APAP.  
Fig. 17. Comparison of the glutathione depletion caused by nitrate esters 24b (MD-38) and 24c 
(MD-39) over 3 h, 6 h and 12 h with APAP and SCP-1 
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Nitrate esters 24b (MD-38) and 24c (MD-39) were also evaluated for necrotic cell death by 
measuring LDH (lactate dehydrogenase) release over a period of 12 h (Fig. 18). At a concentration 
of 500 μM, 24c (MD-39) had higher LDH release than both APAP and SCP-1 over the 12-hour 
period. However, the nitrate ester 24b (MD-38, 500 M) had significantly less LDH release than 
APAP and with similar activity to SCP-1. At the higher concentration of 1000 M, 24b (MD-38) 
had significantly less LDH release than either APAP or SCP-1. This indicates that that 24b (MD-
38) is better tolerated than APAP and exhibits a similar necrotic profile to that of SCP-1. 
Fig. 18. Comparison of the LDH released by nitrate esters 24b (MD-38) and 24c (MD-39) over 
3 h, 6 h and 12 h with APAP and SCP-1 
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As shown in Fig. 19, the cytochrome P450 (CYP450) enzyme profiles were also evaluated for 
the nitrate esters in three human isozymes (CYP3A4, CYP2E1 and CYP2D6) typically involved 
in hepatic drug metabolism. Enzyme inhibition by 24b and 24c was compared to known inhibitors 
ketoconazole (keto), tranylcypromine (TCP) and quinidine as well as to APAP and SCP-1. At a 
concentration of 1 μM, the compounds 24b and 24c were found not to be enzyme inhibitors and 
did not damage the three CYP450 system enzymes tested (CYP3A4, CYP2E1 and CYP2D6). The 
enzyme activity levels were generally higher for 24b and 24c than for APAP in CYP3A4 and 
CYP2E1 enzymes systems and were similar to SCP-1. 
Fig. 19. CYP450 enzyme profiles for 24b (MD-38) and 24c (MD-39). 
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Satisfied that the nitrate esters exhibited a toxicity profile superior to APAP and comparable 
to SCP-1, it was interesting to evaluate the potential NO-donor capability of terms of possible 
enhanced anti-inflammatory activity. It was envisaged that the nitrate esters should exhibit 
enhanced anti-inflammatory activity relative to SCP-1 similar that observed for NO-APAP 
relative to APAP. To this end, the antipyretic activity was evaluated.  SCP-1 does not exhibit 
antipyretic activity, so any reduction fever could be presumed to be due to NO-release from the 
nitrate esters., Yeast-induced fever reduction in rats was determine for 24b and 24c and 
compared to APAP. Rectal temperature was measured 2 hours after the LPS injection and every 
2 hours after compound administration. Fig. 20 illustrates that the antipyretic activity of the 
nitrate ester 24c (MD-39) was significantly different and comparable to APAP at reducing fever 
at the dose tested (1 M). The antipyretic profile of 24b was not significantly different than 
vehicle and was slightly less effective than APAP. 
 




1.11 Water-soluble analogs of SCP-1 and SCP-123 
1.11.1 Attempted synthesis of nitrate ester analogs of SCP-123 
Strategy 1: Following solubility issues, the focus of the project was then shifted toward the 
synthesis of nitrate ester analogs of SCP-123. Since it has been previously established that SCP-1 
is a prodrug and it is converted to SCP-123 in vivo, it was envisioned that the nitrate ester analogs 
of SCP-123 would be more effective and will be more water-soluble. This strategy involved the 
hydrolysis of already synthesized nitrate esters of SCP-1. One equivalent of 0.5 N solution of 
sodium hydroxide was added to 24c and the reaction was left to stir overnight at room temperature. 
However, the 13C NMR showed a shift in the C-ONO2 peak from 73.3 ppm to 56.4 ppm which 
suggests hydrolysis of the nitrate ester to the alcohol 25 (Scheme 12). The reaction was then 
repeated with 0.5 N solution of LiOH and KOH, however, the result was the same. It was therefore 
concluded, that even a dilute solution of LiOH, NaOH and KOH resulted in the hydrolysis of the 
nitrate ester to an alcohol. 
 
Scheme 12. Attempted synthesis of nitrate ester analogs of SCP-123 (Strategy 1) 
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Strategy 2: The next attempt at synthesizing water-soluble analogs involved the hydrolysis of 
the saccharin ring in SCP-1 while simultaneously forming the ester. To achieve this, sodium 2-
bromoethoxide, which was first prepared from sodium hydride and 2-bromo-1-ethanol, was added 
to SCP-1. This produced the bromoester intermediate 26 in moderate yield (66%) (Scheme 13). 
The intermediate 26 was then reacted with AgNO3. The reaction was followed by TLC and it was 
observed that the intermediate had converted to SCP-1 instead of the nitrate ester. It was concluded 
that the heat required for this reaction facilitates ring closure and forms produces SCP-1. 
 
 






1.11.2 O-glycosylation of SCP-1 
Since the attempts at synthesizing nitrate ester analogs of SCP-123 were not successful, a 
different approach was sought to synthesize derivatives that were water-soluble. Incorporating a 
glucose molecule would not only increase the water solubility but also lower the toxicity. It was 
decided that the phenolic OH could by glycosylated using glucose pentaacetate as the donor. 
Instead of glycosylating SCP-1, chloroacetamide (18) was O-glycosylated first after which sodium 
salt of saccharin (15) was added to it. In 1942, Bembry and Powell synthesized phenolic 
glycosides using fully acylated sugar in the presence of phosphorus oxychloride (POCl3) [53]. 
Using the same approach, chloroacetamide 18 was dissolved in anhydrous benzene and reacted 
with -D-glucose pentaacetate (27) in the presence of 99% POCl3/water as the catalyst which 
produced the  anomer of the glycosylated chloroacetamide in 12 % yield (Scheme 14). 
 
Scheme 14. Synthesis of -glycoside tetraacetate of 18 using POCl3 as catalyst 
 In order to achieve higher yields and cleaner reaction conditions, the Schmidt 
glycosylation method was utilized [54]. This method involves the use of a Lewis acid like 
BF3•OEt2 as the catalyst. Using this approach, 18 was dissolved in anhydrous dichloromethane 
(DCM) at 0 ℃ followed by the addition of BF3•OEt2 and  (Scheme 15). The low temperature 
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facilitates the formation of the ortho ester which when heated up gave the O-glycoside as a mixture 
of  and  anomers in 43% and 57% yield respectively. The mixture of anomers was separated 
by column chromatography. 
 
Scheme 15. Synthesis of O-glycoside tetraacetate of 18 using BF3•OEt2 as catalyst 
 The  and  anomers were characterized using 1H NMR spectroscopy. One distinguishable 
characteristic is the spin spin coupling (JH-H) of the anomeric proton. The alpha anomeric proton 
(equatorial) has a coupling constant of about 3 Hz, while the beta anomeric proton (axial) has a 
coupling constant of about 7.9 Hz (Fig. 21).  
  







The structure of 29 was also confirmed using X-ray crystallography (Fig. 22). 
 
Fig. 22. X-ray crystal structure of 29 
 was then treated with the 15 in the presence of a catalytic amount of sodium iodide (NaI). The 
reaction was heated for 2 hours after which it was poured over ice. The -glycoside of SCP-1 (30) 
precipitated in quantitative yield as an off-white solid (Scheme 16). The product was characterized 
by 1H NMR, 13C NMR and mass spectrometry. 
Scheme 16. Synthesis of -O-glycoside tetraacetate of SCP-1 
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The final step involves the deacetylation of the glucose molecule. This was achieved by 
treating the -O-glycoside tetraacetate of SCP-1 (30) with potassium cyanide in anhydrous 
methanol (Scheme 17). The reaction was monitored by TLC which showed the deacetylation of 
every acetyl group one by one as multiple product spots developed. Only one spot remained after 
18 hours which indicated complete deacetylation. The product (31) was obtained as a yellow solid 
in 67% yield. 
 
Scheme 17. Synthesis of -O-glycoside of SCP-1 
1.11.3 Synthesis of amides of SCP-1 
A series of amide analogues of SCP-1 were synthesized. This was achieved by reacting SCP-
1 with various alkyl amino alcohols and amino acids. The nucleophilic amines attacked the 
carbonyl group on the saccharin moiety and then formed the respective amides. First, a series of 
alkyl amino alcohols 32-37 (Fig. 23) were reacted with SCP-1 in ethanol. The reactions were 
heated at reflux overnight. The products 38-43 (Fig. 24) were extracted in ethyl acetate and 
obtained as shiny white solids in low to moderate yields (23-48%) (Scheme 18). These compounds 
were found to be very hygroscopic and water-soluble. This resulted in low yields as a large amount 
of the product dissolved in the aqueous layer during the liquid/liquid extraction. The compounds 




Fig. 23. Alkyl amino alcohols used 
 
 
Scheme 18. Synthesis of amides of SCP-1 using amino alcohols 32-37 
Table 3. Optimized yields of amides 38-43 
Compound no. Amine used Isolated Yield (%) 
38 32 23 
39 33 24 
40 34 24 
41 35 30 
42 36 47 





Fig. 24. Structures of amides of SCP-1 38-43 
The same procedure was also used to synthesize 44 by reacting SCP-1 with ammonia (NH3). 
The reaction was carried out at room temperature without any solvent and gave the product in 
78% yield as a colorless oil (Scheme 19). 
 
Scheme 19. Synthesis of amide 44 
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The scope of the reaction was further explored by using amino acids glycine hydrochloride 
(45) and -alanine methyl ester hydrochloride (46). These reactions required the addition of a base 
which converted the hydrochloride salt into the free base. Two equivalents of sodium bicarbonate 
(NaHCO3) was used for this purpose. Reactions were carried out in methanol and DMF 
respectively to give products 47 and 48 as white solids in moderate yields (49-50%) (Scheme 20). 
Table 4. Synthesis of amides of SCP-1 using amino acids 45 and 46 
Amino acid Amino acid structure Solvent Isolated yield (%) 
45 













1.11.4 Hydrophobicity studies 
 Hydrophobicity studies were conducted on compounds 39-43, 47 and 48. The 
hydrophobicity of any compound can be measured by calculating the logP value where P is the 
partition coefficient between octanol and water. Lower the logP value, the less hydrophobic the 
compound. In general, water-soluble compounds have a logP value of less than 1.  
Equal amounts of octanol and water needed to be stirred overnight. The water-saturated 
octanol layer and octanol-saturated water layer were then stored in separate bottles. The 
Octanol-saturated water was used to prepare 5M, 10 M, 20 M, 40 M and 60 M solutions 
of each compound. UV-vis spectroscopy was used to measure the absorbance between 200-450 
nm (Fig. 25) for each concentration and a calibration curve was produced (Fig. 26).  
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Fig. 26. Calibration curve for 39 at 250 nm 
 
Table 5. Wavelengths used to produce calibration curve for each compound 










Next, seven samples of 50 M solutions were prepared. Six of these samples were shaken 
with water-saturated Octanol for 4 hours. Once it was shaken, some of the sample dissolved in the 
octanol layer. One sample was left unshaken. UV-vis spectroscopy was used to measure the 
absorbance for octanol-saturated water for all seven samples. Using the calibration curve, the 














concentration of the compound in the octanol-saturated water was calculated (Fig. 27) after which 
the average of the six shaken samples were taken.  The concentration of the compound in the 
octanol layer can be calculated by subtracting the concentration of the sample in the water layer 
of the shaken sample from the concentration in water of the unshaken sample. 




 x 100      
Therefore, P = 
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑢𝑛𝑠ℎ𝑎𝑘𝑒𝑛−𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑠ℎ𝑎𝑘𝑒𝑛
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑠ℎ𝑎𝑘𝑒𝑛
 x 100      
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The logP values of compounds 39-43, 47 and 48 are depicted in the chart below (Fig. 28). 
 
Fig. 28. LogP values of the amides compared to SCP-1 and APAP  
Table 6. Comparison between logP and clogP values [55] 
Compound LogP clogP 
39 -0.11 -0.13 
40 -0.48 -0.77 
41 -0.021 0.08 
42 -0.67 -0.77 
43 0.099 0.08 
47 -0.48 -0.45 
































As shown in Fig. 28, the logP values of SCP-1 and APAP are 0.71 and 0.27 respectively. With 
a logP value of greater than 0.5, SCP-1 has very low water solubility and therefore has poor 
bioavailability and also affects the transport of the drug between cell membranes. APAP has a 
lower logP value and therefore is more water-soluble than SCP-1. The amides 39-43, 47 and 48 
have very low logP values with 39-42 and 47 having negative logP values (-0.11, -0.48, -0.021 
and -0.67) and 43 having logP value close to zero. The logP values of the amides are very close 
and comparable to the computational logP (clogP) values (Table 6). These values prove that these 
amides are highly water-soluble and can prove to be ideal drug candidates. This will undoubtedly 













In summary, a series of novel nitrate ester congeners of the acetaminophen derivative SCP-1 
were synthesized. The nitrate esters 24b (MD-38) and 24c (MD-39) exhibited a hepatotoxicity 
profile similar to SCP-1. In addition, the nitrate esters exhibited little effect on the three 
cytochrome P450 isozymes tested (CYP3A4, CYP2E1 and CYP2D6). The nitrate ester 24c (MD-
39) exhibited antipyretic activity similar to APAP. Overall, these preliminary studies 
demonstrated that attachment of a NO-donor moiety to the SCP-1 ring system can lead to 
compounds with enhanced antipyretic activity compared to SCP-1 without increased toxicity. 
Following solubility issues, a series of water-soluble analogs of SCP-1 were synthesized. 
These was achieved by synthesizing O-glycosylated analogs and amide derivatives of SCP-1 A 
series of amides were prepared by hydrolysis of the saccharin moiety. Amides 39-43, 47 and 48 
underwent hydrophobicity studies. All amides were found to be highly water-soluble having low 
logP values comparable to the clogP values. Further testing of these compounds is underway and 










All reactions were carried out in oven-dried glassware under a N2 atmosphere unless otherwise 
noted. All chemicals were purchased from Alfa Aesar, Sigma Aldrich, or VWR and were used as 
received without further purification. Chromatography refers to flash silica gel column 
chromatography (0.060–0.200mm (60 Å) silica gel from Sorbent Technology was used as the 
stationary phase).  1H NMR and 13C NMR spectra were recorded at room temperature in DMSO-
d6 on a Bruker 300 MHz instrument.  
1H chemical shifts were referenced to the DMSO solvent 
signal (2.48 ppm). 13C chemical shifts were referenced to the DMSO solvent signal (40.00 ppm). 
Atlantic Microlab Inc., Norcross, GA performed all CHN microanalyses. 
General procedure A: Preparation of chloroesters of SCP-1 (23a-d) 
SCP-1 (1.00 g, 3.00 mmol) was dissolved in 2% solution of triflic acid in acetonitrile (15 mL) (A 
1% solution was used for the preparation of acetyl ester 23a) followed by the indicated amount of 
acid chloride. The mixture was stirred at room temperature and the reaction was followed by TLC 
(70% EtOAC-Hex). When no more starting material was seen by TLC, the mixture was poured 
over ice-cold water (50 mL) and extracted with ethyl acetate (3 x 20 mL). The organic layer was 
washed with 1N HCl (20 mL), saturated NaHCO3 (20 mL) and brine (20 mL). The organic layer 
was then dried over anhydrous sodium sulfate. The sodium sulfate was filtered and the solvent 







General procedure A. Product was prepared using chloroacetyl chloride (0.720 mL, 9.00 mmol, 
3 equiv., 16 h) and was isolated as a white solid (1.21 g, 99% yield). mp 199.1-200.0 ℃.  
1H NMR (DMSO-d6, 300 MHz) : 10.45 (s, 1H), 8.36 (d, J = 7.7, 1H), 8.17 (d, J = 7.7Hz, 1H), 
8.12-8.01 (m, 2H), 7.61 (d, J = 8.8, 2H), 7.15 (d, J = 8.8, 2H), 4.68 (s, 2H), 4.59 (s, 2H).  
13C NMR (DMSO-d6, 75 MHz) : 166.8, 163.7, 159.1, 146.3, 137.4, 136.8, 136.4, 135.7, 126.8, 




General procedure A. Product was prepared using 3-chloropropionyl chloride (0.86 mL, 9.0 
mmol, 3 equiv., 16 h) and was isolated as a white solid (1.24 g, 98% yield). mp 195.3-197.0 ℃.  
1H NMR (DMSO-d6, 300 MHz) : 10.41 (s, 1H), 8.34 (d, J = 7.7 Hz. 1H)), 8.15 (d, J = 7.4 Hz, 
1H), 8.05 (dt, J = 23.1, 7.4 Hz, 2H), 7.58 (d, J = 8.9, 2H), 7.08 (d, J = 8.9, 2H), 4.57 (s, 2H), 3.88 
(t, J = 6.2 Hz, 2H), 3.08 (t, J = 6.2 Hz, 2H).  
13C NMR (DMSO-d6, 75 MHz) : 169.6, 163.7, 159.1, 146.3, 137.4, 136.6, 136.4, 135.8, 126.8, 






General procedure A. Product was prepared using 4-chlorobutyryl chloride (0.5 mL, 4.5 mmol, 
1.5 equiv., 1 h) and was isolated as a white solid (1.30g, 99% yield). mp 189.2-190.6 ℃.  
1H NMR (DMSO-d6, 300 MHz) : 10.40 (s, 1H), 8.34 (d, J = 9 Hz, 1H), 8.15 (d, J = 7.3 Hz, 1H), 
8.11-8.00 (m, 2H), 4.57 (s, 2H), 3.72 (t, J = 6.4 Hz, 2H), 2.70 (t, J = 7.2 Hz, 2H), 2.06 (p, J = 7.0 
Hz, 2H).  
13C NMR (DMSO-d6, 75 MHz) : 171.5, 163.7, 159.1, 146.5, 137.4, 136.3, 135.7, 126.8, 125.6, 




General procedure A. Product was prepared using 5-chlorovaleroyl chloride (0.43 mL, 3.3 
mmol, 1.1 equiv., 1 h) and was isolated as a white solid (1.34g. 99% yield). mp (154.4-155.9 ℃).  
1H NMR (DMSO-d6, 300 MHz) : 10.40 (s, 1H), 8.35 (d, J = 7.5 Hz, 1H), 8.15 (d, J = 7.0 Hz, 
1H), 8.00-8.17 (m, 2H), 7.57 (d, J = 8.9 Hz, 2H), 7.07 (d, J = 8.9 Hz, 2H), 4.57 (s, 2H), 3.67 (t, J 
= 6.1 Hz, 2H), 2.60 (t, J = 7.1 Hz, 2H), 1.82-1,70 (m, 4H).  
13C NMR (DMSO-d6, 75 MHz) : 172.1, 163.7, 159.1, 146.5, 137.4, 136.4, 136.4, 133.8, 126.8, 




General procedure B: Preparation of nitrate esters of SCP-1 (24b-d) 
The chloroester (3.00 mmol) was dissolved in dry acetonitrile (20 mL) and silver nitrate (1.02g, 
6.00 mmol) was then added to the solution. The mixture was heated at reflux for 24 h. The 
precipitate was filtered through a pad of Celite. The filtrate was then poured into water (50 mL) 
and extracted with ethyl acetate (3 x 20 mL). The organic layer was washed with brine (3 x 20 
mL) and dried over anhydrous sodium sulfate. The sodium sulfate was filtered and the solvent 




(nitrooxy)propionate (MD-38, 24b) 
General procedure B. Product was isolated as a yellow solid (1.29g, 96% yield). mp 174.3 ℃ 
(decomp).  
1H NMR (DMSO-d6, 300 MHz) : 10.41 (s, 1H), 8.34 (d, J = 8.3 Hz, 1H), 8.15 (d, J = 7.4 Hz, 
1H), 8.11-7.99 (m, 2H), 7.58 (d, J = 8.8 Hz, 2H), 7.08 (d, J = 8.8 Hz, 2H), 4.57 (s, 2H), 3.89 (t, J 
= 6.2 Hz, 2H), 3.08 (t, J = 6.2 Hz, 2H).  
13C NMR (DMSO-d6, 75 MHz) : 169.3, 163.7, 159.1, 146.3, 137.4, 136.6, 136.4, 135.8, 126.8, 
125.6, 122.4, 122.2, 120.6, 69.3, 32.0. 





(nitrooxy)butanoate (MD-39, 24c) 
General procedure B. Product was isolated as a yellow solid (1.25g, 90% yield). mp 159.1 ℃ 
(decomp.). 
1H NMR (DMSO-d6, 300 MHz) : 10.42 (s, 1H), 8.36 (d, J = 7.7 Hz, 1H), 8.16 (d, J = 7.3 Hz, 
1H), 8.06 (dt, J = 15.4, 7.4 Hz, 2H), 7.58 (d, J = 8.7 Hz, 2H), 7.11 (d, J = 8.7 Hz, 2H), 4.61 (t, J = 
5.8 Hz, 2H), 4.59 (s, 2H), 2.70 (t, J = 7.0, 2H), 2.03 (p, J = 6.9 Hz, 2H).  
13C NMR (DMSO-d6, 75 MHz) : 171.6, 163.7, 159.1, 146.5, 137.4, 136.5, 126.8, 125.6, 122.5, 
122.2, 120.5, 73.2, 30.2, 22.1. 
Anal. calcd. for C19H17N3O9S: C, 49.24; H, 3.70; N, 9.07. Found: C, 49.18; H, 3.75; N, 9.00. 
4-(2-(1,1-dioxido-3-oxobenzo[d]isothiazol-2(3H)-yl)acetamido)phenyl 5-
(nitrooxy)pentanoate (24d) 
General procedure B. Product was isolated as a yellow solid (1.33g, 93% yield). mp 144.6 ℃ 
(decomp.).  
1H NMR (DMSO-d6, 300 MHz) : 10.41 (s, 1H), 8.34, (d, J = 7.7, 1H), 8.15 (d, J = 8.0, 1H), 8.11-
7.99 (m, 2H), 7.57 (d, J = 8.9 Hz, 2H), 7.08 (d, J = 8.9 Hz, 2H), 4.58 (s, 1H), 4.55 (t, J = 6.1 Hz, 
2H), 2.62 (t, J = 6.8 Hz, 2H), 1.81-1.63 (m, 4H).  
13C NMR (DMSO-d6, 75 MHz),  172.0, 163.7, 159.1, 146.5, 137.4, 136.4, 135.6, 126.8, 125.6, 
122.5, 122.1,121.4,120.6, 73.8, 33.1, 25.8, 21.0. 




2H-pyran-3,4,5-triyl triacetate (O-glycoside of chloroacetaminophen, 29) 
2-Chloroacetaminophen (0.501g, 2.70 mmol) was dissolved in anhydrous dichloromethane (20 
mL). followed by the addition of -D-Glucose pentaacetate (0.952g, 2.44 mmol). The mixture 
was cooled in an ice bath to 0 ℃. BF3•OEt2 (0.452 mL, 3.66 mmol) was then added to the solution 
dropwise and the reaction was stirred at 0 ℃ for 30 minutes. The reaction was then heated at 
reflux for 18 hours. The reaction was quenched with 1N NaOH solution and the layers were 
separated. The aqueous layer was extraction with dichloromethane (3 x 10 mL). The organic layers 
were combined and washed with brine (20 mL). The organic layer was dried over anhydrous 
Na2SO4 and filtered. The solvent was removed under vacuum and the residue was purified using 
column chromatography (50% EtOAc/Hexanes). The  anomer was isolated as a colorless oil 
(0.717g, 57% yield). 
1H NMR (DMSO-d6, 300 MHz) : 10.23 (s, 1H), 7.50 (d, J = 9.0 Hz, 2H), 6.95 (d, J = 10.3 Hz, 
2H), 6.15 (d, J = 3 Hz, 1H), 5.45 (t, J = 9.9 Hz, 1H), 5.32 (t, J = 9.9 Hz, 1H), 5.10-4.97 (m, 2H), 
4.21 (s, 2H), 4.02-3.97 (m, 2H), 2.16 (s, 12H). 
Preparation of 2-(acetoxymethyl)-6-(4-(2-(1,1-dioxido-3-oxobenzo[d]isothiazol-
2(3H)-yl)acetamido)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (-D-
glycoside of SCP-1, 30) 
29 (1.50 g, 3.00 mmol) and 15 (0.743g, 3.62 mmol) were dissolved in anhydrous DMF (20 mL). 
Sodium iodide (0.0500g, 0.300 mmol) was then added to it. The reaction was stirred at 110 ℃ 
for 2 h. Any solids were filtered off and the filtrate was poured over ice-water. More ice was 
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added until no more precipitate formed. The precipitate was filtered off and dried under vacuum 
to give 30 as a yellow solid (2.00 g, 100% yield). mp 196-198 ℃ 
1H NMR (DMSO-d6, 300 MHz) : 10.28 (s, 1H), 8.34 (d, J = 7.7 Hz, 2H), 8.20 – 7.98 (m, 3H), 
7.50 (d, J = 8.1 Hz, 2H), 6.96 (d, J = 9.0 Hz, 2H), 5.47 (d, J = 7.8 Hz, 1H), 5.38 (t, J = 9.6 Hz, 





30 (2.00g, 3.00 mmol) was dissolved in anhydrous MeOH (20 mL) and potassium cyanide (0.100 
g, 1.51 mmol) was added to it. The reaction was stirred at room temperature for 18 h. The mixture 
was passed through a silica gel plug. The solvent was removed under vacuum to give 32 as a 
yellow solid (1.00 g, 67% yield). mp 152 ℃ (decomp.) 
1H NMR (DMSO-d6, 300 MHz) : 10.27 (s, 1H), 8.33 (d, J = 7.7 Hz, 2H), 8.11-7.95 (m, 3H), 7.53 
(d, J = 9.0 Hz, 2H), 6.96 (d, J = 9.0 Hz, 2H), 5.83 (d, J = 7.8 Hz, 1H), 4.21 (s, 2H), 3.96-3.42 (m, 
10 H). 
General procedure C: Preparation of amides of SCP-1 (38-43, 47-48) 
SCP-1 (1.00g, 3.00 mmol) was dissolved in absolute ethanol (30 mL). The amino alcohol 32-37 
(9.00 mmol) was added to the reaction mixture. The solution was stirred at reflux for 24 h. The 
reaction mixture was cooled down to room temperature and then diluted with deionized water (50 
mL). The aqueous solution was extracted with ethyl acetate (3 x 20 mL). The organic layers were 
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combined and washed with 2N HCl (20 mL) and brine (20 mL). The organic layer was dried over 




General procedure C. The product was prepared using 32 (1.00 mL, 9.00 mmol) and was isolated 
as a light pink solid (0.300 g, 23 % yield). 
1H NMR (DMSO-d6, 300 MHz) : 9.75 (s, 1H), 9.18 (s, 1H), 8.75 (t, J = 5.6 Hz, 1H), 7.87 (d, J 
= 7.5 Hz, 1H), 7.71 – 7.5 (m, 2H), 7.52 (d, J = 7.3 Hz, 1H), 7.42 (t, J = 5.9 Hz, 1H), 7.19 (d, J = 
8.9 Hz, 2H), 6.63 (d, J = 8.9 Hz, 2H), 3.65 (d, J = 5.9 Hz, 2H), 3.39 (t, J = 6.4 Hz, 2H), 3.23 (q, J 
= 6.8 Hz, 2H), 1.45 (dtd, J = 33.9, 14.6, 5.9 Hz, 9H). 
13C NMR (DMSO-d6, 75 MHz) : 168.7, 165.8, 154.0, 138.0, 137.3, 136.3, 133.2, 130.3, 129.7, 
129.0, 121.4, 115.5, 61.1, 46.4, 32.7, 29.0, 23.4. 
2-(N-(2-((4-hydroxyphenyl)amino)-2-oxoethyl)sulfamoyl)-N-(3-
hydroxypropyl)benzamide (39) 
General procedure C. The product was prepared using 33 (0.700 mL, 9.00 mmol) and was 
isolated as a white solid (0.300 g, 24 % yield). 
1H NMR (DMSO-d6, 300 MHz) : 9.75 (s, 1H), 8.72 (t, J = 5.6 Hz, 1H), 7.86 (d, J = 9.0 Hz, 1H), 
7.70 – 7.57 (m, 2H), 7.52 (d, J = 8.8 Hz, 1H), 7.43 (t, J = 5.9 Hz, 1H), 7.19 (d, J = 8.9 Hz, 2H), 
57 
 
6.63 (d, J = 6.8 Hz, 2H), 3.65 (d, J = 5.9 Hz, 2H), 3.48 (t, J = 6.3 Hz, 2H), 3.30 (q, J = 6.6 Hz, 
2H), 1.68 (p, J = 6.5 Hz, 2H). 
13C NMR (DMSO-d6, 75 MHz) : 168.7, 165.8, 154.0, 137.3, 136.3, 133.2, 130.3, 129.7, 129.0, 
121.4, 115.5, 59.0, 46.4, 37.2, 32.4. 
Anal. Calcd. for C18H21N3O6S•H2O: C, 50.81; H, 5.45; N, 9.88. Found: C, 50.80; H, 5.47; N, 9.78 
N-(1,3-dihydroxypropan-2-yl)-2-(N-(2-((4-hydroxyphenyl)amino)-2-
oxoethyl)sulfamoyl)benzamide (40) 
General procedure C. The product was prepared using 34 (0.820 mL, 9.00 mmol) and isolated 
as a white solid (0.305g, 24 % yield). 
1H NMR (DMSO-d6, 300 MHz) : 9.78 (s, 1H), 9.19 (s, 1H), 8.56 – 8.41 (m, 1H), 7.84 (d, J = 8.7 
Hz, 1H), 7.74 (t, J = 6.0 Hz, 1H), 7.67 – 7.61 (m, 1H), 7.59 – 7.52 (m, 2H), 7.10 (d, J = 8.8 Hz, 
2H), 6.61 (d, J = 8.8 Hz, 2H), 4.86 (t, J = 5.3 Hz, 2H), 3.93 (dt, J = 7.9, 5.7 Hz, 1H), 3.76 – 3.70 
(m, 2H), 3.53 (t, J = 5.4 Hz, 4H). 
13C NMR (DMSO-d6, 75 MHz) : 168.1, 166.2, 154.1, 137.1, 136.7, 133.1, 130.2, 130.0, 129.80, 
129.0, 121.7, 115.48, 60.6, 54.3, 46.1. 








General procedure C. The product was prepared using 35 (0.700 mL, 9.00 mmol) and isolated 
as a white solid (0.366 g, 30 % yield). 
1H NMR (DMSO-d6, 300 MHz) : 9.78 (s, 1H), 8.76 (t, J = 6.3 Hz, 1H), 7.84 (d, J = 7.7 Hz, 1H), 
7.68 – 7.51 (m, 5H), 7.12 (d, J = 8.9 Hz, 2H), 6.61 (d, J = 8.9 Hz, 2H), 3.81 (q, J = 5.9 Hz, 1H), 
3.69 (d, J = 5.9 Hz, 2H), 3.53 (s, 2H), 3.40 (s, 3H), 3.24 –3.15 (m, 1H). 
13C NMR (DMSO-d6, 75 MHz) : 168.1, 165.7, 153.6, 136.1, 132.8, 129.8, 129.3, 128.6, 121.2, 
115.1, 65.1, 47.0, 45.8, 21.1. 
 Anal. Cald. for C18H21N3O6S•H2O: C, 50.81; H, 5.45; N, 9.88. Found: C, 50.81; H, 5.49; N, 9.86. 
N-(2,3-dihydroxypropyl)-2-(N-(2-((4-hydroxyphenyl)amino)-2-
oxoethyl)sulfamoyl)benzamide (42) 
General procedure C. The product was prepared using 36 (0.700 mL, 9.00 mmol) and isolated 
as a white solid (0.600 g, 47% yield). 
1H NMR (DMSO-d6, 300 MHz) : 9.76 (s, 1H), 9.18 (s, 1H), 8.72 (t, J = 6.3 Hz, 1H), 7.85 (dd, J 
= 7.6, 1.1 Hz, 1H), 7.66 (td, J = 7.6, 1.4 Hz, 1H), 7.61 – 7.56 (m, 2H), 7.56 – 7.52 (m, 1H), 7.13 
(d, J = 8.9 Hz, 2H), 6.61 (d, J = 8.9 Hz, 2H), 4.94 (d, J = 4.8 Hz, 1H), 4.57 (t, J = 5.2 Hz, 1H), 
3.72 – 3.68 (m, 2H), 3.38 (t, J = 5.6 Hz, 2H), 3.29 (s, 2H), 3.19 – 3.03 (m, 1H). 
13C NMR (DMSO-d6, 75 MHz) : 168.6, 166.0, 154.0, 137.2, 136.4, 133.1, 130.2, 129.8, 129.0, 
121.6, 115.5, 70.6, 64.2, 46.2, 43.3. 
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Anal. Calcd. for C18H21N3O7S: C, 51.06; H, 5.00; N, 9.92. Found: C, 50.88; H, 5.25: N, 9.76. 
2-(N-(2-((4-hydroxyphenyl)amino)-2-oxoethyl)sulfamoyl)-N-(2-
hydroxypropyl)benzamide (43) 
General procedure C. The product was prepared using 37 (0.700 mL, 9.00 mmol) and isolated 
as a white solid (0.600 g, 48% yield). 
1H NMR (DMSO-d6, 300 MHz) : 9.78 (s, 1H), 8.76 (t, J = 6.3 Hz, 1H), 7.84 (d, J = 7.7 Hz, 1H), 
7.68 – 7.51 (m, 5H), 7.12 (d, J = 8.9 Hz, 2H), 6.61 (d, J = 8.9 Hz, 2H), 3.81 (q, J = 5.9 Hz, 1H), 
3.69 (d, J = 5.9 Hz, 2H), 3.53 (s, 2H), 3.40 (s, 3H), 3.24 –3.15 (m, 1H). 
13C NMR (DMSO-d6, 75 MHz) : 168.1, 165.7, 153.6, 136.1, 132.8, 129.8, 129.3, 128.6, 121.2, 
115.1, 65.1, 47.0, 45.8, 21.1. 
Anal. Calcd. for C18H21N3O6S: C, 53.06; H, 5.20; N, 10.31. Found: C, 52.99; H, 5.40; N, 10.07. 
2-(2-(N-(2-((4-hydroxyphenyl)amino)-2-oxoethyl)sulfamoyl)benzamido)acetic 
acid (47) 
SCP-1 (1.00g, 3.00 mmol) was dissolved in absolute MeOH (30 mL). Glycine hydrochloride (1.00 
g, 9.00 mmol) and NaHCO3 (0.504 g, 6.00 mmol) were added to the reaction mixture. The solution 
was stirred at reflux for 24 h. The reaction mixture was cooled down to room temperature and 
then diluted with deionized water (50 mL). The aqueous solution was extracted with ethyl acetate 
(3 x 20 mL). The organic layers were combined and washed with 2N HCl (20 mL) and brine (20 
mL). The organic layer was dried over anhydrous Na2SO4, filtered and the solvent was removed 
under vacuum to give amide 47 as a white solid (0.600 g, 49% yield). 
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1H NMR (DMSO-d6, 300 MHZ) : 9.73 (s, 1H), 9.18 (s, 1H), 9.07 (t, J = 5.9 Hz, 1H), 7.93 – 
7.81 (m, 1H), 7.74 – 7.66 (m, 1H), 7.65 – 7.55 (m, 2H), 7.48 (t, J = 5.9 Hz, 1H), 7.15 (d, J = 8.8 
Hz, 2H), 6.61 (d, J = 8.8 Hz, 2H), 3.98 (d, J = 5.8 Hz, 2H), 3.69 (d, J = 6.0 Hz, 2H). 
13C NMR (DMSO-d6, 75 MHz) : 171.6, 168.7, 165.9, 154.0, 137.4, 135.7, 133.2, 130.5, 129.9, 
129.1, 121.5, 115.5, 46.2, 41.5. 




SCP-1 (1.00g, 3.00 mmol) was dissolved in anhydrous DMF (30 mL). -Alanine methyl ester 
hydrochloride (1.26 g, 9.00 mmol) and NaHCO3 (0.504 g, 6.00 mmol) were added to the reaction 
mixture. The solution was stirred at 90 ℃ for 24 h. The reaction mixture was cooled down to room 
temperature and then diluted with deionized water (50 mL). The aqueous solution was extracted 
with ethyl acetate (3 x 20 mL). The organic layers were combined and washed with 2N HCl (20 
mL) and brine (20 mL). The organic layer was dried over anhydrous Na2SO4, filtered and the 
solvent was removed under vacuum to give amide 48 as a white solid (0.653 g, 50% yield). 
1H NMR (DMSO-d6, 300 MHz) : 9.73 (s, 1H), 9.18 (s, 1H), 8.89 – 8.78 (m, 1H), 7.86 (d, J = 7.5 
Hz, 1H), 7.63 (dq, J = 14.1, 6.9 Hz, 2H), 7.49 (d, J = 7.2 Hz, 1H), 7.39 (s, 1H), 7.18 (d, J = 8.8 





13C NMR (DMSO-d6, 75 MHz) : 171.8, 168.5, 165.4, 153.6, 136.9, 135.6, 132.8, 130.0, 129.2, 
128.6, 121.1, 115.1, 51.5, 45.9, 35.4, 33.1. 





































The 3,3-diarylazetidine ring has recently emerged as an important molecular scaffold in 
medicinal chemistry. The constrained 3,3-diarylazetidine ring system provides a well-defined 
positioning of the arene substituents, increased rigidity, fewer rotatable bonds relative to 
corresponding acyclic system and can be isosteric with N-diarylmethylamines and geminal diaryl 
functional groups. With the emerging interest in 3,3-diarylazetidines as novel motifs in drug 
discovery programs, an easy, efficient, scalable synthetic method that could accommodate the 
introduction of both electron-rich and electron-deficient aryl groups for preparation of diversely 
substituted 3,3-diarylazetidines would be valuable to medicinal chemists. In this second project, a 
versatile synthesis of 3,3-diaryl azetidines from N-Boc-3-aryl-3-azetidinols using Friedel-Crafts 
arylation conditions with AlCl3 is described. A series of substituted diaryl azetidines were readily 
prepared and isolated as the oxalate salts in high yield and high purity.  The 3,3-diaryl azetidine 












The importance of diarylalkanes as pharmaceutically active compounds has been well 
documented. Various diarylmethane based molecules like podophyllotoxin (49), peperomin B 
(50), tolterodine (51) and lasofoxifene (52)  exhibit antibacterial, antiprotozoal, anti-
inflammatory, antimuscarinic and anticonvulsant activity [56] [57] [58] [59]. 
 




2.1.1 Synthesis of diarylmethanes 
Diarylmethanes have mostly been synthesized via Friedel–Craft’s alkylation of the 
corresponding benzyl alcohols with another arene, metal catalyzed cross coupling of aryl halides 
with benzyl nucleophiles, metal catalyzed cross coupling of benzyl halides with aryl nucleophiles 
and C–C bond formation between tosyl hydrazones and aryl boronic acids. 
2.1.1.1 Friedel–Crafts reaction 
In 1997, S. Fukuzawa et al. reported trifluoromethane sulfonic acid (TFSA) catalyzed 
reductive Friedel–Craft’s alkylation of benzaldehyde acetals for the preparation of diarylmethanes 
(Scheme 21) [60]. When low boiling arenes were used, the arene served as the solvent as well as 
the reagent while for high boiling arenes 1,2-dichloroethane or nitromethane was used as a solvent. 
Though both electron rich as well as electron poor aldehyde acetals responded to this reaction, the 
reaction rate was faster with the electron rich aldehyde acetals with the ratio of ortho:meta:para 
ratio being same as that observed for general Lewis acid catalyzed Friedel–Craft’s alkylation 
reaction.  
 




Sun et al. in 2006 reported indium (III) chloride catalyzed electrophilic substitution of 
trioxanes with arenes for the preparation of diarylmethanes [61]. The authors found that the 
reaction was high yielding only with electron rich arenes while electronically poor ones gave low 
yield. Later, the authors reported indium trichloride acetyl acetone to be an efficient Lewis catalyst 
for the Friedel–Craft’s arylation of benzyl alcohols for the efficient preparation of diarylmethanes 
(Scheme 22) [62].  
 
Scheme 22. Synthesis of diarylmethanes using indium (III) chloride as catalyst 
In 2009, Myrboh et al. reported AlCl3 catalyzed Friedel–Craft’s alkylation of benzylazines 
with polynuclear hydrocarbons to form diarylmethanes in aprotic solvents [63]. The 
corresponding azines were accessed from the respective carbonyl compounds through 
condensation with aqueous solution of hydrazines. 
Mendoza et al. in 2011 reported Bronsted acid catalyzed arylation of benzyl acetates and anisyl 
acetates with arenes for the preparation of diarylmethanes (Scheme 23) [64]. Trifluoromethane 




Scheme 23. Bronsted and Lewis acid catalyzed arylation 
2.1.1.2 Metal-free C-C bond formation 
In 2009, Barluenga et al. reported metal free C-C bond formation for the synthesis of 
diarylmethanes from tosyl hydrazones [65]. Boronic acids were used as the aryl source. The 
authors proposed heating the tosyl hydrazone salts in presence of a base generates the diazo 
intermediate. This intermediate reacts with aryl boronic acids to form the benzyl boronic acid. The 
formation of benzyl boronic acid can be explained either through the intermediate formation of a 
boronate or through the formation of a carbene (through the loss of nitrogen molecule). Reaction 
of the carbene with the boronic acid forms the benzyl boronic acid. Protodeboronation of the 
benzyl boronic acid led to the formation of the product (Scheme 24). 
 
Scheme 24. Synthesis of diarylmethane using metal free C-C bond formation 
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In 2012, Khodaei et al. reported triphenyl phosphine ditriflate (TPPD) mediated Friedel–
Craft’s alkylation of benzyl alcohols with arenes for the facile preparation of diarylmethanes 
(Scheme 25) [66]. 
 
Scheme 25. Synthesis of diarylmethanes using triphenyl phosphine ditriflate 
2.1.1.3 Copper and Palladium catalyzed cross coupling reactions 
In 1996, Ku et al. reported copper catalyzed cross coupling of aryl Grignard reagents with 
benzyl halides for the preparation of diarylmethanes [67] (Scheme 26). This was a high yielding, 
easily scalable reaction for the preparation of diarylmethanes for multigram industrial scale. 
 
Scheme 26. Copper catalyzed synthesis of diarylmethanes using Grignard reagent 
Leibeskind et al. reported in 1997 and 1999, metal catalyzed cross coupling reactions of 
heterobenzylic sulfonium salts with organostannanes, organoboronic acids as well as organozinc 
reagents [68] [69] (Scheme 27). For the cross coupling with organostannanes and organoboronic 
acids, palladium was used while for organozinc halides, nickel was used. For improving the 
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efficiency of the organostannanes, Ph2P(O)O
-Bu4N
+ was used as Bu3Sn scavenger. The use of 
highly nucleophilic phosphine ligands in order to stabilize the metal catalyst and the electrophilic 
sulfonium salts leads to the competing side reactions which were overcome by using essentially 
non-nucleophilic triaryl phosphites as ligands. 
 
Scheme 27. Palladium catalyzed synthesis of diarylmethanes using organostannates 
2.1.1.4 Suzuki-Miyaura coupling 
Georghiou et al. in 1999 reported the Suzuki–Miyaura coupling of benzyl halides with aryl 
and naphthyl boronic acids to form the respective diarylmethanes [70] (Scheme 28). The authors 
observed using benzyl iodides caused a minor increase in the reaction yield compared to benzyl 
bromides. Using benzyl bromides required a higher catalyst loading and the reaction took longer 
to reach completion. 
 
Scheme 28. Synthesis of diarylmethanes using Suzuki-Miyaura coupling 
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In 2006, Molander et al. reported Suzuki coupling of benzyl halides with potassium 
aryltrifluoroborates for the preparation of diarylmethanes [71]. The pre-catalyst used was 
PdCl2(dppf).CH2Cl2 (Scheme 29). 
 
Scheme 29. Synthesis of diarylmethanes using potassium aryltrifluoroborates 
2.1.1.5 Stille coupling 
Monteiro et al. reported Stille coupling of benzylic halides with aryl tributyl tin for the 
preparation of diarylmethanes with palladium acetate as the palladium source, diphenyl 
phosphinyl ferrocene (dppf) as the ligand and potassium fluoride as a base in dioxane as solvent 
[72]. However, when the reaction was carried out in the absence of a base, triphenyl phosphine 
was found to be a better ligand (Scheme 30). 
 
Scheme 30. Synthesis of diarylmethanes using Stille coupling 
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2.1.1.6 Kumada coupling  
Sarkar and coworkers in 2010 developed a novel air stable bidentate ligand having an indole 
moiety and N–P donor atom for the Nickel catalyzed Kumada coupling of aryl and benzyl 
chlorides with aryl magnesium halides [73]. The Kumada coupling reactions of the benzyl 
chlorides with the aryl magnesium halides were highly reactive yielding the corresponding 
diarylmethanes in high yields (up to 90% yield) (Scheme 31). 
 
 
Scheme 31. Synthesis of diarylmethanes using Kumada coupling 
2.1.1.7 Hiyama coupling 
Sarkar et al. in 2010 reported palladium nanoparticles as catalyst for the Hiyama coupling of 
benzylic halides with aryl trialkoxy silanes [74]. The authors further demonstrated the importance 
of this methodology by synthesizing the natural product 2,4-bis(4-hydroxybenzyl) phenol in only 




Scheme 32. Synthesis of 2,4-bis(4-hydroxybenzyl) phenol using Hiyama coupling 
2.1.1.8 Negishi coupling 
In 2012, Lipshutz et al. reported a remarkably simple method to develop unsymmetrical 
diarylmethanes that relies on an in situ organozinc-mediated, palladium-catalyzed cross-coupling 
[75]. Thus, by mixing a benzyl and aryl halide together in the presence of Zn metal and 
a Pd catalyst, diarylmethanes are formed at room temperature without assistance by a surfactant 
(Scheme 33). 
 
Scheme 33. Synthesis of diarylmethanes using Negishi coupling 
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2.1.1.9 Lewis acid mediated sp3 C–O bond activation 
Shi et al. in 2008 reported FeCl3 mediated sp
3 C–O activation of benzyl ethers for the Friedel–
Craft’s alkylation of benzyl ethers with arenes [76] (Scheme 34). 
 
Scheme 34. Lewis acid mediated synthesis of diarylmethanes  
In 2012, Kraus et al. reported Lewis acid catalyzed rearrangement of benzylic ethers for the 
facile preparation of diarylmethanes [77] (Scheme 35).  
 





2.1.2 Diarylmethanes in drug discovery 
Diarylmethanes are very important scaffolds in organic and medicinal chemistry. Some have 
been used as dyes [78] [79], protecting groups for nucleosides, carbohydrates [80] [81] anticancer 
drugs [82] epoxy resins, and antioxidants [83]. Piritrexim (53), a lipophilic inhibitor of the key 
metabolic enzyme dihydrofolate reductase (DHFR) has been studied intensively as an anticancer 
drug (Fig. 28). A noble structural feature of 53 is a methylene (CH2) bridge between the two halves 
of the molecule. This bridge is also present in trimethoprim (54), another lipophilic DHFR 
inhibitor widely used for therapy in AIDS patients, usually in combination with a sulfa drug to 
enhance efficacy. Another member of this class that has been used clinically against these 
infections is trimetrexate (55), which contains a longer CH-NH bridge [84] (Fig. 30). 
 
 
Fig. 30. Structures of 53, 54 and 55 showing the diarylmethane scaffold 
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In 2006, Panda et al. reported the synthesis of a series of aminoalkyl derivatives of substituted 
and unsubstituted diarylmethanes (Fig. 31). These compounds were evaluated for antitubercular 
activity. Indole and phenanthrene substituted derivatives showed promising activity against M. 
tuberculosis H37Rv. 
 
Fig. 31. Structures of substituted and unsubstituted diarylmethanes 56-59 
Gout is the most common inflammatory arthritis caused by the deposition of monosodium 
urate (MSU) in articular and periarticular tissues and characterized by recurrent joint swelling, 
redness, warmth and severe pain [85]. If left untreated or poorly managed, tophaceous gout will 
ultimately lead to permanent joint destruction, bone erosion and kidney impairment, dramatically 
affecting patients’ quality of life and even threatening their lives [86]. Recently, Cai and coworkers 
developed uric acid transporter 1 (URAT1, SLC22A12) inhibitors, for the treatment of gout, that 
contained a diarylmethane backbone. Structure-activity relationship (SAR) studies were carried 
out on the general backbone. The authors synthesized 33 compounds out of which 60 was found 




Fig. 32. Structure of URAT1 inhibitor 60 
2.2 Heterocycles in drug discovery 
Heterocycles are key scaffold components in medicinal chemistry. They are fundamental 
building blocks of most drugs on market today (Fig. 33). The importance of heterocycles is well 
understood by modern medicinal chemists, since they play a significant role in molecular 
properties such as the electronic distribution, three dimensionality, and scaffold rigidity. They are 
often key factors in whole molecule properties such as lipophilicity or polarity and can determine 
molecular reactivity, metabolic stability, and toxicity [87]. Most frequently, nitrogen heterocycles 
or various positional combinations of nitrogen atoms, sulphur, and oxygen in five or six-
membered rings can be found in many drugs. According to statistics, more than 85% of all 




Fig. 33. Top 10 heterocyclic scaffolds in FDA approved drugs 
2.2.1 Four-membered nitrogen heterocycles: Azetidines 
With the exception of a single aziridine-containing drug (mitomycin), the most commonly 
found for-membered nitrogen heterocycles are all β-lactams, of which 95% are fused to another 
ring with the nitrogen atom shared (Fig. 34) [88]. They are least diverse in terms of diseases they 
are used to treat. Case in point, all but the cholesterol lowering agent ezetimibe [89] of the β-
lactam drugs [90] are antibiotics or used in combination with antibiotics. 
 
Fig. 34. Top four most common four-membered nitrogen heterocycles 
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2.2.1.1 Syntheses of azetidines 
Cyclization of a preformed chain by nucleophilic displacement of a leaving group by a 
nitrogen nucleophile is, by far, the most common method to produce azetidines. Amines are the 
most common nitrogen nucleophiles [91]. In 2006, Ju et al. reported the synthesis of N-substituted 
azetidine by cyclization of aniline with 1,3-dichloropropane. The reaction was carried out in water 
by the assistance of microwave (Scheme 36) [92]. 
 
Scheme 36. Synthesis of N-substituted azetidine 
Traditional protocols in the presence of alcoholic intermediates involve the transformation of 
the alcohol in sulfonic ester, mainly mesylate [93] [94] [95] tosylate [96] [97] [98] and triflates 
[99]  followed by base mediated cyclization. Hillier and co-worker reported the synthesis of 1,3- 
substituted azetidines from 2-substituted-1,3-propanediols in a one-pot reaction (Scheme 37). 
 
Scheme 37. Synthesis of 1,3 substituted azetidine 
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De Kimpe’s group provided the synthesis of uncommon 3,3-dichloroazetidines (Scheme 38) 
[100] and 3-fluoroazetidines (Scheme 39) [101] starting from imines. 
 
Scheme 38. Synthesis of 3,3-dichloroazetidines 
 
Scheme 39. Synthesis of 3-fluoroazetidines 
2.3 Azetidines as a pharmaceutical scaffold 
Azetidine is considered a privileged scaffold in drug discovery. It is a good compromise 
between a satisfactory stability and a strong molecular rigidity, allowing an efficient tuning of 
pharmacological properties displayed by molecules bearing this moiety [102]. Azetidines, despite 
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their indisputable importance as bioactive compounds and pharmaceutical tools, have received 
little attention by the chemical community compared to the higher homologous counterparts.  
There are very few azetidine containing drugs are currently on the market. Dihydropyridine 
azelnipidine (Calblock, 61) is Sankyo’s calcium channel blocker [103]. Exelixis’ cobimetinib 
(Cotellic, 62), as a targeted cancer therapy, is a mitogen-activated protein kinase-1/2 (MEK1/2) 
inhibitor (Fig. 35) [104].  
 
Fig. 35. Structures of azetidine-based drugs 61 and 62 
 
Another azetidine-containing drug ximelagatran (Exanta, 63) as a direct thrombin inhibitor 
was discovered by AstraZeneca. Initially sold as an anticoagulant, it was pulled off the market in 




Fig. 36. Structure of azetidine-based drug 63 
Azetidine carbamate 64 is an efficient, covalent inhibitor of monoacylglycerol lipase (MAGL) 
discovered by Pfizer [106]. The hexafluoroisopropanol (HFIP) group here serves as the leaving 
group when attacked by the key serine residue (Ser122) at the enzyme’s active site. Fatty acid 
amide hydrolase (FAAH) inhibitors are potential treatment for pain. Vernalis discovered a mixture 
of chiral azetidine-ureas VER-24052 (65) as a FAAH inhibitor (Fig. 37) [107]. 
 
Fig. 37. Structures of azetidine-based drugs 64 and 65 
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In 2013, Roche reported an azetidine-containing bis-amide 66 as a selective JAK3 (Janus 
kinase) inhibitor (IC50 = 0.26 nM) with a 10-fold selectivity over JAK1 (IC50 = 3.2 nM). In 
addition, the combination of its selectivity over the kinome, good solubility and reasonable 
exposure was translated to in vivo potency and selectivity in an acute PK/PD mouse model (Fig. 
38) [108]. 
 
Fig. 38. Structure of azetidine-based drug 66 
2.3.1 Synthesis of bioactive azetidines 
 Sankyo’s synthesis of azelnipidine (Calblock, 61) began with 1-benzhydryl- 3-
hydroxyazetidine, readily assembled from condensation of benzhydrylamine with 
epichlorohydrin. Subsequent 1,3- dicyclohexylcarbodiimide (DCC)-mediated esterification with 
cyanoacetic acid produced ester, which was converted to an amidine in two additional steps. A 
Hantzsch dihydropyridine synthesis between the amidine and an enone then delivered azelnipidine 





Scheme 40. Synthesis of AzeInipidine 61 
Exelixis’ synthesis of cobimetinib (Cotellic, 62) commenced with addition of a piperidine-
Grignard reagent to N-Cbz-3-azetidinone. The resulting 3-hydroxy azetidine underwent 
Palladium-catalyzed hydrogenation, removing the Cbz protection, to afford the exposed azetidine. 
Ester formation from the coupling between the free azetidine and an acid chloride in the presence 




Scheme 41. Synthesis of Cotellic 62 
2.4 Geminal 3,3-diaryl azetidines 
The combination of saturated heterocycles with aromatic substituents provide particularly 
attractive screening compounds as fragments or lead-like compounds due to the different potential 
binding interactions available. However there remain challenges in readily accessing a broad array 
of substituted heterocycles under mild conditions, as is appropriate in divergent and iterative 
medicinal chemistry investigations [109]. The sp3-sp2 coupling of small rings or saturated 
heterocycles with aromatic components presents a valuable transformation that can facilitate the 
construction of important compound types in drug discovery.  3,3-Diarylazetidines are relatively 





Fig. 39. Bioactive geminal diaryl azetidine structures 
2.5 Synthesis of 3,3-diarylazetidines: Recent developments and scope 
In 2019, Bull and coworkers reported the synthesis of 3,3-diarylazetidines by Fridel-Craft’s 
alkylation of electron rich aromatics with azetidinols, using a calcium triflimide catalyst [112]. A 
calcium catalyst generates azetidine carbocations from 3-arylazetidin-3-ols under mild conditions. 
The reaction was compatible with functionalized substrates and a wide range of electron-rich 
aromatic and heteroaromatic nucleophiles. The azetidinols were prepared using Grignard’s 
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reagents (Scheme 42). The resulting 3-aryl-3-azetidinols were then reacted with various aromatic 
nucleophiles to give the corresponding 3,3-diarylazetidines. 
 
Scheme 42. Synthesis of 3-aryl-3-azetidinols 
Initially, the authors examined N-Cbz azetidinols bearing a 4-methoxyphenyl group using 
catalytic amounts of various Lewis acids and phenols such as o-cresol as nucleophiles (Scheme 
43). Optimization studies for Fridel-Craft’s arylation of azetidinol 67 with o-cresol is shown in 
Table 5. 
 





Table 7. Fridel-Craft’s aryltion of 67 with o-cresol. 
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The Bu4NPF6 additive was crucial, with no reaction in its absence (Table 5-entry 4). 
Decreasing the equivalents of the phenol from 5 to 3 maintained high yield (94%). Solvents like 
toluene and heptane were suitable but dichloromethane was used because of improved substrate 
solubility. These optimized conditions were then used to investigate the scope of the reaction. A 






Scheme 44. Synthesis of 3,3-diarylazetidines 68b-o 
Table 8. Scope of heteroaromatics and phenol derivatives as nucleophiles 























































The Cbz group was removed by using H2, Pd/C catalyst to give the free-base azetidine 69 
(Scheme 45), important for further functionalization. 
 





2.5 Design strategy for synthesis of 3,3-diarylazetidines and subsequent 
derivatization 
Previous studies in our group have reported the synthesis of 3,3-diarylazetidines from N-Boc-
3-azetidinols [113]. The N-Boc-3-azetidinols were prepared from the readily available N-Boc-3-
azetidinone. This was achieved by reacting the azetidinone with aryllithium reagents. 
Subsequently, the azetidinols underwent Friedel-Craft’s arylation using aluminum chloride 
(AlCl3) as the Lewis acid. It was observed that the AlCl3 not only assists in the nucleophilic attack 
of the aryl group but also deprotects the Boc group to give the free-base azetidine. 
The goal of this project was to functionalize 3,3-diarylazetidines previously synthesized in the 
group. Scheme 46 shows the she retrosynthetic approach for the synthesis of the functionalized 
3,3-diarylazetidines. The 3,3-diarylazetidines will have to be prepared first. These diarylazetidines 
will be functionalized by adding acyl and alkyl groups to the azetidine nitrogen. 
 
Scheme 46. Retrosynthetic scheme for synthesis of N-functionalized 3,3-diarylazetidines 
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RESULTS AND DISCUSSION 
2.6 Synthesis of N-boc-3-aryl-3-azetidinols 
Previously used synthetic methodology was used to synthesize the diarylazetidines. The series 
of diarylazetidizes was synthesized in two steps. The first step involved the reaction of an 
aryllithium compound with N-Boc-3-azetidinone (70). The arryllithium was prepared in situ using 
a metal-halogen exchange between n-butyllithium (n-BuLi) and an aryl halide. Synthesis of N-
Boc-3-phenyl-3-azetidinone was attempted first. Bromobenzene was treated with n-BuLi in 
Tetrahydrofuran (THF) at -78 ℃ to give phenyllithium after which 70 was added to the reaction 
mixture and stirred at room temperature overnight to give N-Boc-3-phenyl-3-azetidinol (71a) 
(Scheme 47). 
 
Scheme 47. Synthesis of N-Boc-3-phenyl-3-azetidinol 71a 
The mechanism for this reaction is shown in Scheme 48. The reaction takes place via a 





Scheme 48. Mechanism of nucleophilic addition of phenyllithium 
71a was isolated by column chromatography. The first few attempts resulted in very low yields 
(42%). The major product of the reaction was found to be homocoupled product 72 (presumably 
biphenyl). Initially, 72 was mistaken as the desired product on the TLC plate (Rf = 0.5) and isolated 
using column chromatography. However, 1H NMR showed peaks only in the aromatic region (⁓7-
8 ppm). This homocoupled product could have formed via Wurtz coupling. This happens when 
the lithiated product (phenyllithium) reacts with the aryl halide (bromobenzene) (Scheme 49).  
This required us to reevaluate the TLC plate. There was a faint UV active spot with an Rf value 
of 0.3 which was isolated using column chromatography. 1H NMR confirmed its identity as 71a.  
 
Scheme 49. Possible side reaction and formation of homocoupled product 72 
To increase the yield of 71a and reduce the formation of 72, the amount of bromobenzene 
added was reduced from 3 equivalents to 2 equivalents. This reduced the formation of the 
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homocoupled product 72 but didn’t increase the yield of the azetidinol 71a drastically (62% yield). 
Next, the concentration of phenyllithium in THF was investigated. It was concluded that using 1.3 
equivalents and 0.25 M solution of the aryllithium gave a small amount of 72 and 71a was obtained 
in high yield (96%). Table 7 shows the optimization studies for this reaction. 
Table 9. Optimization studies for the synthesis of 71a 
Entry Equiv. of n-BuLi Molarity of n-BuLi in THF (M) Yield of 63a (%) 
1 3 1.1 42 
2 3 0.44 62 
3 2 0.12 63 
4 2 0.30 72 
5 1.3 0.25 96 
 
Using the optimized conditions azetidinols 71a-c were prepared. Using electron withdrawing 
groups like chlorine and fluorene resulted in lower yields of the azetidinols (Scheme 50). 
 
Scheme 50. Synthesis of N-Boc-3-aryl-3-azetidinols 71a-c 
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2.7 Synthesis of 3,3-diarylazetidines 
The 3,3-diarylazetidines were prepared from the azetidinols 71a-c by Friedel-Crafts arylation 
reaction using AlCl3 as the Lewis catalyst. This reaction can proceed via two mechanisms. The 
AlCl3 could first remove the Boc group to give the free base azetidinol. It then enhances the 
electrophilicity of the azetidinol by creating a complex with it. The O-H group is removed by 
AlCl3 creating a bicyclic compound 73. The nucleophilic benzene attacks the electrophilic 
carbocation to give the desired diaryl product 74a (Scheme 51 and 52). 
 
 




Scheme 52. Friedel-Crafts arylation mechanism after Boc removal 
Alternatively, the N-Boc-3-azetidinol could get arylated first via Friedel-Crafts arylation 
after which the Boc group would be removed (Scheme 53 and 54). 
 




Scheme 54. Boc removal after Friedel-Crafts aylation 
At the end of the reaction, The TLC plate showed a UV active spot corresponding to the N-
Boc-3-arylazetdinol as well as a spot on the baseline which could either correspond to the free 
base 3-arylazetidinol or some other impurities. It was concluded that it is likely that the Boc group 
was removed after the Friedel-Crafts arylation which would explain the N-Boc-3-arylazetidinol 
on the TLC plate at the end of the reaction. 
As summarized in Table 8, the azetidinols 71a-c and a variety of substituted benzenes (20 
equiv.) were treated with AlCl3 without solvent at 0 °C for 2h to furnish the Friedel-Crafts 
arylation products 74a-h (Scheme 55). The Boc-protecting group was removed during this step, 
which allowed the azetidine to be easily isolated as the oxalic acid salt. This avoided the need for 
chromatography and any additional purification steps. As the oxalate salts the 3,3-diarylazetidines 




Scheme 55. Synthesis of 3,3-diarylazetidine oxalic acid salts 
Table 10. Optimized yields of 3,3-diarylazetidine oxalic acid salts 
Entry 71 X Y Yield of 74 (%) 
a 71a H H 86 
b 71a H CH3 83 
c 71a H F 60 
d 71a H Cl 86 
e 71a H OCH3 72 
f 71b F H 63 
g 71c Cl H 70 
h 71c Cl Cl 81 
 
As seen in Table 10, both electron withdrawing and donating groups were tolerated and the 
3,3-diarylazetidines were synthesized in moderate to good yields (60-86%). However, it was 
observed that halogenated benzenes with electron withdrawing groups like fluorine gave lower 
yields. This is seen in entry c when adding fluorobenzene lowers the yield to 60%. Activating 




2.8 Synthesis of N-functionalized 3,3-diarylazetidines 
To demonstrate versatility of the 3,3-arylazetidine salts 74 toward further functionalization at 
nitrogen, the preparation of a series of N-substituted analogues was explored. Initially, N-
alkylation of 3,3-diarylazetidine oxalic acid salt 74a was carried out with benzyl bromide. As 
illustrated in Table 11, a variety of bases (Et3N; NaHCO3, Na2CO3, t-BuOK, NaH, n-BuLi) and 
solvents (EtOH, THF and DMF) were used.  
Table 11. Optimization of N-alkylation of 74a 
Entry Base Solvent Yield of 75a (%) 
1 Et3N EtOH 46 
2 Et3N DMF 52 
3 Na2CO3 DMF 56 
4 t-BuOK THF 32 
5 NaH EtOH 63 
6 NaH DMF 82 





While many combinations of base and solvent gave modest yields of the N-alkylation 
product, it was determined that using NaHCO3 (3 equivalents) in DMF at 110 ℃ furnished 75a in 
90% yield. It was also determined that using DMF as the solvent in general gave higher yields as 
the reaction could be heated to a higher temperature when compared to THF and EtOH. The 
optimized conditions were then applied to N-alkylation with 3-bromoethylpropionate to give 75b 
in 94% yield. The reaction conditions were also tolerated with aromatic compounds like 2-
bromopyridine. However, the N-arylated product 75c was obtained in only 54% yield (Scheme 
56). 
 
Scheme 56. N-alkylation of 74a 
To further investigate the scope of this reaction, the 3,3-diarylazetidines were acylated at the 
nitrogen using benzoyl chloride. Both symmetrical and unsymmetrical 3,3-diarylazetidines were 







Table 12. N-alkylated products of 74a 



















In summary, we have developed a simple method for the preparation of 3,3-diarylazetidines 
using AlCl3-mediated Friedel-Crafts arylation of N-Boc-3-aryl-3-azetidinols. The conditions 
allowed for incorporation of both electron-rich and electron-deficient aryl groups to furnish the 
3,3-diarylazetidines in good yield as stable oxalic acid salts. The salts exhibit exceptional shelf 
life and can be efficiently converted into N-alkylated, N-arylated and N-acylated derivatives of 
the 3,3-diarylazetidines. With easy access to the 3,3-diarylazetidines, this moiety will undoubtedly 






All reactions were carried out in oven-dried glassware under a N2 atmosphere unless otherwise 
noted. All chemicals were purchased from Alfa Aesar, Sigma Aldrich, VWR and CNH 
Technologies and were used as received without further purification. Chromatography refers to 
flash silica gel column chromatography (0.060–0.200mm (60 Å) silica gel from Sorbent 
Technology was used as the stationary phase).  1H NMR and 13C NMR spectra were recorded at 
room temperature in DMSO-d6 on a Bruker 300 MHz instrument.  
1H chemical shifts were 
referenced to the DMSO solvent signal (2.48 ppm). 13C chemical shifts were referenced to the 
DMSO solvent signal (40.00 ppm). Atlantic Microlab Inc., Norcross, GA performed all CHN 
microanalyses. 
General procedure A: Preparation of N-Boc-3-aryl-3-azetidinol (71a-c) 
Bromobenzene or halogenated bromobenzene (40 mmol) was dissolved in anhydrous THF (144 
mL) and cooled to -78 ℃. To this flask, n-BuLi (2.5 M, 40 mmol, 32 mL) was added dropwise. 
The mixture was stirred at -78 ℃ for 10 minutes. N-boc-3-azetidinone (1, 3.4 g, 20 mmol) was 
dissolved in anhydrous THF (4 mL) and then slowly added via syringe to the reaction mixture. 
The mixture was allowed to warm to room temperature and stirred overnight. The reaction was 
quenched with water, extracted with diethyl ether (3 x 100 mL) and the combined organic layers 
were washed with brine (100 mL). The organic portion was dried over anhydrous sodium sulfate, 
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filtered and the solvent was removed under vacuum. The crude oil was purified by column 
chromatography (30% EtOAc:hexanes) to afford the 3-arylazetidinol 63a-c as a pale-yellow solid. 
N-Boc-3-phenyl-3-azetidinol (71a) 
According to General Procedure A, the reaction was performed with bromobenzene (6.2 g, 40 
mmol). The azetidinol 63a was obtained as a pale-yellow solid (4.8 g, 96% yield). mp 85.3-87.8 
℃. 
1H NMR (DMSO-d6, 300 MHz) : 7.48 (d, J = 7.7 Hz, 2H), 7.36 (t, J = 7.5 Hz, 2H), 7.27 (m, 1H), 
6.31 (s, 1H), 4.02 (s, 4H), 1.40 (s, 9H).  
13C NMR (DMSO-d6, 75 MHz) : 156.3, 145.1, 128.6, 127.5, 125.0, 79.2, 70.1, 65.1, 28.5. 
N-Boc-3-(4-fluorophenyl)-3-azetidinol (71b)  
According to General Procedure A, the reaction was performed with 4-fluorobromobenzene (7.0 
g, 40 mmol). The azetidinol 63b was obtained as a pale-yellow solid (3.8 g, 72% yield). mp 90.8-
92.8 ℃.  
1H NMR (DMSO-d6, 300 MHz) : 7.53-7.49 (m, 2H), 7.17-7.12 (m, 2H), 6.39 (s, 1H), 4.02 (s, 
4H), 1.39 (s, 9H).  
13C NMR (DMSO-d6, 75 MHz) : 163.3, 160.1, 156.3, 141.3, 127.1, 127.0, 115.4, 115.1, 79.2, 





According to General Procedure A, the reaction was performed with 4-chlorobromobenzene (7.6 
g, 40 mmol). The azetidinol 63c was obtained as a pale-yellow solid (4.8 g, 86% yield). mp 139.0-
140.6 ℃.  
1H NMR (DMSO-d6, 300 MHz) : 7.50 (d, J = 8.7 Hz, 2H), 7.42 (d, J = 8.7 Hz, 2H), 6.43 (s, 1H), 
4.00 (s, 4H), 1.40 (s, 9H).  
13C NMR (DMSO-d6, 75 MHz) : 156.3, 144.2, 132.2, 128.6, 127.0, 79.4, 69.7, 65.2, 28.5. 
General Procedure B: Preparation of 3,3-diarylazetidine oxalate salts (74a-h) 
Aluminum chloride (4.0 g, 30 mmol) was suspended in benzene or halogenated benzene (20 
mmol) and cooled to 0 ℃ in an ice bath under an atmosphere of nitrogen. N-Boc-3-aryl-3-
azetidinol (2, 10 mmol) was dissolved in benzene or substituted benzene and added to the reaction 
mixture via syringe. The reaction mixture was then stirred at 0 ℃ for 2 h under nitrogen. The 
reaction was quenched with ice and stirred for 30 minutes. Saturated sodium bicarbonate solution 
(20 mL) was added to the mixture followed by ammonium hydroxide to achieve a pH of 11. The 
mixture was the extracted with diethyl ether (3 x 20 mL) and washed with brine (20 mL). The 
organic layer was dried over anhydrous sodium sulfate, filtered and the solvent removed under 
vacuum. The residue was then dissolved in a minimum amount of diethyl ether and an ether 
solution of oxalic acid (10 mmol) was added dropwise to the residue solution. The oxalate salt 




3,3-Diphenylazetidine hydrogen oxalate (74a) 
General procedure B. The product was obtained from 71a and benzene as a white solid (2.57 g, 
86% yield). mp 230.5-232.3 ℃.   
1H NMR (DMSO-d6, 300 MHz) : 9.30 (s, 1H), 7.43 (d, J = 7.5 Hz, 4H), 7.35 (t, J = 7.6 Hz, 4H), 
7.23 (t, J = 7.3 Hz, 2H), 4.62 (s, 4H).  
13C NMR (DMSO-d6, 75 MHz) : 162.8, 146.6, 129.0, 127.0, 126.6, 61.3, 60.4, 48.3.  
Anal. Calcd. for C15H15N•(CO2H)2: C, 68.22; H, 5.72; N, 4.68. Found: C, 68.01; H, 5.88; N, 4.55. 
3-(4-Methylphenyl)-3-phenyl-azetidine hydrogen oxalate (74b) 
General procedure B. The product was obtained from 71a and toluene as a white solid (2.23 g, 
71% yield). mp 185.6-187.6 ℃.   
1H NMR (DMSO-d6, 300 MHz) : 7.40, (d, J = 7.8 Hz, 2H), 7.63-7.27 (m, 4H), 7.25-7.15 (m, 
3H), 4.58, (s, 4H), 2.23 (s, 3H).   
13C NMR (DMSO-d6, 75 MHz) : 165.3, 146.2, 143.1, 136.7, 129.3, 127.4, 126.4, 115.6, 57.3, 
48.9, 21.1.  





3-(4-Fluorophenyl)-3-phenylazetidine hydrogen oxalate (74c) 
General procedure B. The product was obtained from 71a and fluorobenzene as a white solid 
(1.90 g, 60% yield). mp 164.2-166.4 ℃.   
1H NMR (DMSO-d6, 300 MHz) : 7.51-7.41 (m, 4H), 7.35 (t, J = 7.5 Hz, 2H), 7.25-7.15 (m, 3H), 
4.61 (s, 4H).  
13C NMR (DMSO-d6, 75 MHz) : 164.4, 162.8, 160.4, 145.9, 142.2, 129.4, 128.8, 128.7, 127.5, 
126.5, 126.2 116.2, 116.0, 57.3, 48.7, 31.7.  
Anal. Calcd. for C15H14NF•(CO2H)2: C, 64.35; H, 5.09; N, 4.41. Found: C, 64.13; H, 5.15; N, 
4.25. 
3-(4-Chlorophenyl)-3-phenylazetidine hydrogen oxalate (74d).  
General procedure B. The product was obtained from 71a and chlorobenzene as a white solid 
(2.86 g, 86% yield). mp 214.6-217.6 ℃.  
1H NMR (DMSO-d6, 300 MHz) : 7.47 (d, J = 8.6 Hz, 2H), 7.43-7.40 (m, 4H), 7.38 – 7.33 (m, 
2H), 7.27 – 7.21 (m, 1H), 4.60 (s, 4H).   
13C NMR (DMSO-d6, 75 MHz) : 164.8, 145.2, 144.7, 132.0, 129.2, 129.1, 128.3, 127.4, 126.2, 
57.0, 48.6.  





3-(4-Methoxyphenyl)-3-phenylazetidine hydrogen oxalate (74e).   
General procedure B. The product was obtained from 71a and anisole as a white solid (2.36 g, 
72% yield). mp 160.0-162.8 ℃.  
1H NMR (DMSO-d6, 300 MHz) : 9.49 (s, 1H), 7.49-7.32 (m, 6H), 7.23 (m 1H), 6.89 (d, J = 8.6 
Hz, 2H), 4.57 (s, 4H), 3.70 (s, 3H).  
13C NMR (DMSO-d6, 75 MHz) : 158.4, 146.1, 137.7, 129.1, 127.6, 127.1, 126.2, 114.2, 57.1, 
55.6, 48.6.  
Anal. Calcd. for C16H17NO•(CO2H)2•H2O: C, 62.24; H, 6.09; N, 4.03. Found: C, 62.03; H, 6.37; 
N, 3.75. 
3-Phenyl-3-(4-fluorophenyl)azetidine hydrogen oxalate (74f) 
General procedure B. The product was obtained from 71b and benzene (1.99 g, 63% yield). mp 
164.2-166.4 ℃.   
1H NMR (DMSO-d6, 300 MHz) : 7.51-7.41 (m, 4H), 7.35 (t, J = 7.5 Hz, 2H), 7.25-7.15 (m, 3H), 
4.61 (s, 4H).  
13C NMR (DMSO-d6, 75 MHz) : 164.4, 162.8, 160.4, 145.9, 142.2, 129.4, 128.8, 128.7, 127.5, 
126.5, 126.2 116.2, 116.0, 57.3, 48.7, 31.7.  





3-Phenyl-3-(4-chlorophenyl)azetidine hydrogen oxalate (74g) 
General procedure B. The product was obtained from 71c and chlorobenzene as a white solid 
(2.33 g, 70% yield). mp 214.6-217.6 ℃.  
1H NMR (DMSO-d6, 300 MHz) : 7.47 (d, J = 8.6 Hz, 2H), 7.43-7.40 (m, 4H), 7.38 – 7.33 (m, 
2H), 7.27 – 7.21 (m, 1H), 4.60 (s, 4H).   
13C NMR (DMSO-d6, 75 MHz) : 164.8, 145.2, 144.7, 132.0, 129.2, 129.1, 128.3, 127.4, 126.2, 
57.0, 48.6.  
Anal. Calcd. for C15H14NCl•(CO2H)2: C, 61.18; H, 4.48; N, 4.20. Found: C, 60.95; H, 4.78; N, 
3.94. 
3,3-Di(4-chlorophenyl)azetidine hydrogen oxalate (74h) 
General procedure B. The product was obtained from 71c and chlorobenzene as a white solid 
(2.87 g, 81% yield). mp 219.6-221.1 ℃.  
1H NMR (DMSO-d6, 300 MHz) : 9.63 (s, 1H), 7.47 (d, J = 8.1 Hz, 4H), 7.41 (d, J = 7.9 Hz, 4H), 
4.54 (s, 4H).   
13C NMR (DMSO-d6, 75 MHz) : 144.5, 135.5, 132.32, 129.4, 128.6, 56.9, 48.3.  





General procedure C: Preparation of N-substituted 3,3-diarylazetidines  
3,3-Diarylazetidine oxalate salt (1 equiv.) was dissolved in anhydrous DMF (20 mL) followed by 
the addition of the alkyl, aryl or acyl bromide (3 equiv) and NaHCO3 (4 equiv). The mixture was 
heated at 110 ℃ for 16 h. The reaction was poured into water (100 mL) and extracted with diethyl 
ether (3 x 20 mL). The combined organic layers were washed with water (5 x 10 mL), brine (20 
mL), dried over anhydrous Na2SO4 and filtered. The solvent was removed under vacuum. The 
residue was then purified. 
N-Benzyl-3,3-diphenylazetidine (75a) 
General procedure C. The product was prepared using 74a (0.500 g, 1.67 mmol), benzyl bromide 
(0.600 mL, 5.01 mmol) and NaHCO3 (0.561 g, 6.68 mmol) and was purified by column 
chromatography (50% EtOAc:hexanes). The product was obtained as a pale-yellow oil. (0.450 g, 
90% yield).   
1H NMR (DMSO-d6, 300 MHz) : 7.38-7.20 (m, 15 H), 5.47 (s, 2H), 3.48 (s, 4H).   
13C NMR (DMSO-d6, 75 MHz) : 139.6, 128.8, 128.7, 128.3, 128.3, 127.4, 115.1, 57.4.   
Anal. Calcd for C22H21N: C, 88.25; H, 7.07; N, 4.68. Found: C, 88.19; H, 7.00; N, 4.53. 
Ethyl-3-(3,3-diphenylazetidinyl)-propionate hydrogen oxalate (75b) 
General procedure C. The product was prepared using 74a (0.500 g, 1.67 mmol), ethyl 3-
bromopropionate (0.630 mL, 5.01 mmol) and NaHCO3 (0.561 g, 6.68 mmol). The residue was 
dissolved in a minimal amount of diethyl ether. Oxalic acid dissolved in a minimal amount of 
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diethyl ether was then added to it. The oxalate salt precipitated out as an off-white solid and was 
collected by vacuum filtration. (0.614 g, 92% yield). mp 185.0 ℃ (decomp.)   
1H NMR (DMSO-d6, 300 MHz) :  7.39 (d, J = 7.4 Hz, 4H), 7.32 (t, J = 6.6 Hz, 4H), 7.20 (t, J = 
6.6 Hz, 2H), 4.46 (s, 4H), 4.06 (q, J = 6.6 Hz, 2H), 3.17 (t, J = 7.4 Hz, 3H), 2.52(t, J = 7.2 Hz, 
2H), 1.16 (t, J = 7.1 Hz, 3H).   
13C NMR (DMSO-d6, 75 MHz) : 170.6, 163.0, 145.7, 128.6, 126.6, 126.0, 64.8, 60.4, 51.7, 46.6, 
30.5, 14.1.  
Anal. Calcd for C20H23NO2•C2H2O4•H2O: C, 63.30; H, 6.52; N, 3.36. Found: C, 63.10; H, 6.50; 
N, 3.21. 
N-(2-Pyridinyl)-3,3-diphenylazetidine (75c) 
General procedure C. The product was prepared using 74a (0.200 g, 0.668 mmol), 2-
bromopyridine (0.200 mL, 2.00 mmol) and NaHCO3 (0.300 g, 2.67 mmol). The product was 
isolated and purified using column chromatography (50% Ethyl acetate: Hexanes) to obtain a 
colorless oil (0.103 g, 54% yield). 
1H NMR (DMSO-d6, 300 MHz) : 8.07 (d, J = 6Hz, 1H), 7.52 (t , J = 6 Hz, 1H), 7.39-7.29 (m, 
8H), 7.19 (t, J = 6 Hz, 2H), 6.65 (t, J = 6 Hz, 1H), 6.47 (d, J = 6 Hz, 1H), 4.45 (s, 4H). 






General procedure C. The product was prepared using 74a (0.500 g, 1.67 mmol), benzoyl 
chloride (0.600 mL, 5.01 mmol) and NaHCO3 (0.561 g, 6.68 mmol). The product was isolated 
and purified using column chromatography (50% Ethyl acetate: Hexanes) to obtain a white solid. 
(0.502g, 96% yield). mp 179.4-181.0 ℃.  
1H NMR (DMSO-d6, 300 MHz) : 7.66 (d, J = 7.3 Hz, 2H), 7.56 – 7.43 (m, 3H), 7.39 (d, J = 8.1 
Hz, 4H), 7.32 (t, J = 7.5 Hz, 4H), 7.20 (t, J = 6.7 Hz, 2H), 4.93 (s, 2H), 4.71 (s, 2H).  
13C NMR (DMSO-d6, 75 MHz) : 169.2, 146.5, 131.2, 128.6, 128.5, 127.9, 126.5, 126.3, 65.9, 
61.67, 46.7.   
Anal. Calcd for C22H19NO: C, 84.31; H, 6.11; N, 4.47. Found: C, 84.08; H, 5.96; N, 4.40. 
N-Benzoyl-3-(4-chlorophenyl)-3-phenylazetidine (76b)  
General procedure C. The product was prepared using 74d (0.360 g, 1.08 mmol), benzoyl 
chloride (0.376 mL, 3.24 mmol) and NaHCO3 (0.363 g, 4.32 mmol). The product was isolated 
and purified using column chromatography (50% Ethyl acetate: Hexanes) to obtain a colorless oil 
(0.323 g, 86% yield).  
1H NMR (DMSO-d6, 300 MHz) : 7.69 – 7.61 (m, 2H), 7.50 (d, J = 6.9 Hz, 1H), 7.45 (d, J = 7.2 
Hz, 2H), 7.37 (d, J = 14.7 Hz, 7H), 7.31 (d, J = 7.9 Hz, 1H), 7.21 (q, J = 7.1, 5.9 Hz, 1H),  4.90 
(s, 2H), 4.68 (s, 2H).  
13C NMR (DMSO-d6, 75 MHz) : 169.5, 146.4, 145.8, 133.2, 131.6, 129.1, 128.9, 128.7, 128.3, 
127.1, 126.7, 66.1, 61.9, 46.7.  
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A general synthesis of pyruvate esters was developed. Using this method, a series of alkyl 
pyruvate esters were synthesized in moderate to high yields (56-93%). This synthesis can be used 
to synthesize both mono-pyruvate and di-pyruvate esters. This was achieved in four steps starting 
from the readily available triethyl-2-phosphonopropionate which was converted to the alkene 
ethyl 2,3-dimethyl-2-butenoate using Horner-Wadsworth-Emmons reaction. The ethyl ester was 
hydrolyzed to the corresponding carboxylic acid after which a series of esters were prepared using 














3.1 Keto acids 
Keto acids contain two oxygen-containing functional groups: the carboxylic acid (COOH) 
and ketone group (C=O) [114]. There are three classes of keto acids: alpha-keto acid, beta-keto 
acid and gamma-keto acid (Fig. 40). Out of these three, particularly important in biology are the 
α-keto acids (keto group adjacent to the carboxylic acid), since they are involved in the Krebs 
cycle and in glycolysis [115]. 
 
Fig. 40. Alpha, beta and gamma keto esters 
-Keto acids, especially the -keto acid analogues of the naturally occurring amino acids, are 
of major importance in intermediary metabolism. Thus, pyruvic acid is a metabolite involved in a 
number of enzyme-catalyzed intracellular phenomena, and oxaloacetic acid (77), -ketoglutaric 
acid (78), and oxalosuccinic acid (79) are intermediates in the tricarboxylic acid cycle (Krebs’s 






Fig. 41. Structures of -keto acids 
3.1.1 Properties of keto acids 
The straight-chain -keto acids are either liquids or low-melting solids. The branched-chain 
and phenyl-substituted -keto acids vary from liquids to high-melting solids [119] [120]. Some a-
keto acids are unstable as the free acid and exhibit a tendency to decarboxylate and polymerize. 
The majority are relatively stable as salts, of which the sodium and barium salts have most often 
been prepared. In general, -keto acids are relatively stable in neutral solution and can be stored 
frozen at -20 ℃ with little decomposition, but there are notable exceptions. It is well-known that 
pyruvic acid (80) readily polymerizes on storage in aqueous solution to DL--hydroxy--methyl-
-ketoglutaric acid (81) and higher molecular weight compounds [121]. 
 
Fig. 42. Polymerization of Pyruvic acid 
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Schellenberger and coworkers noted that the molecular weight of pure trimethyl pyruvic acid 
(82) when measured cryoscopically in dioxane, up to 0.01 mol fraction was 10% greater than 
expected [122]. Since association by hydrogen bonding is unlikely, it was concluded that some 
dimerization occurred (Scheme 58). Subsequently, crystalline dimer was obtained from cold 
samples of trimethyl pyruvic acid. Glucksmann first isolated the dimer in 1989 [123]. It was 
concluded from dipole measurements and from infrared spectroscopic data that the dimer was an 
"activated ester" (83). 
 
Scheme 58. Dimerization of trimethyl pyruvic acid 
It is well-known that many -keto acids are metabolized via enzyme-catalyzed oxidative 
decarboxylation (i.e. via pyruvate, -ketoglutarate, and branched-chain -keto acid 
dehydrogenases) [124]. It is also well-known that -keto acids are rapidly and quantitatively 
decarboxylated by such mild oxidizing reagents as ceric sulfate [125], hydrogen peroxide 
[126], peroxyphthalic acid [127], potassium permanganate [128], and lead tetraacetate [129]. 
In 1979, Seigel and coworkers reported decarboxylation of -keto acids by hydrogen peroxide 
(H2O2) is base catalyzed and is accelerated in the presence of Fe
2+ (but not other cations) [130]. 
In aqueous solutions of H2O2, 84 undergoes relatively slow decarboxylation to form 85 in 
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quantitative yields. The addition of catalytic amounts of ferrous (Fe2+) salts to the reaction 
mixture cause a dramatic rate enhancement, without reducing the yield of 85 (Scheme 59). 
 
Scheme 59. Oxidative decarboxylation of -keto acid 84 
In 1947, Waters reported that -keto acids can be reduced by hydrogen to the corresponding 
-hydroxy acid [119]. It has been known for more than 30 years that lactate dehydrogenase is 
nonspecific and that it catalyzes the reduction of a large number of -keto acids to the 
corresponding -hydroxy acids (87), some of these -keto acids are reduced at rates similar to 
that found with pyruvate (Scheme 60)  [131]. 
 
Scheme 60. Reduction of -keto acids 
In addition to decarboxylation and reduction, -keto acids are also susceptible to free-radical 
induced fragmentation. In 1968, Evans and Leermakers reported photolysis reactions of -
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ketodecanoic acid [132]. -ketodecanoic acid (88) on photolysis, was found to split into 1-heptene 
(89) and pyruvic acid (80) (Scheme 61). 
 
Scheme 61. Photolysis of -keto acid 88 
3.1.2 Synthesis of -keto acids 
The first -keto acid to be prepared was pyruvic acid (80). This compound was prepared by 
Berzelius in 1835 [133]. Many of the more biologically important a-keto acids were prepared over 
75 years ago, e.g., oxaloacetic (oxalacetic) (77) and a-ketoglutaric (78). Waters lists the methods 
of synthesis of 36 -keto acids. Many of the -keto acids have been prepared by unique methods 
[119]. Some of the recent developments for the synthesis of -keto acids have been described 
below. 
In 1994, Wasserman and Ho reported the synthesis of -keto acids using 
(cyanomethylene)phosphoranes [134]. In this method, (cyanomethylene)phosphoranes (90) was 
coupled with carboxylic acids or acid chlorides to give cyano keto phosphoranes (91). 91 then 
undergoes oxidation and subsequent nucleophilic attack to give an -keto ester (92) which can be 




Scheme 62. Synthesis of -keto acid using (cyanomethylene)phosphoranes 
This method however, produced stoichiometric amount of waste from phosphorus reagents. 
Therefore, a more atom-economical approach was necessary. 
Crich and coworkers developed a selenium-catalyzed oxidation of ketones to prepare aryl-
substituted glyoxylic acids using iodoxybenzene (PhIO2) as the oxidizing agent and fluorous 
selenic acid (10 mol %) as the catalyst [135]. By using a biphasic fluorous system, the fluorous 
phase containing the catalyst could be recovered and reused in new reactions. The method was 
successfully applied in the synthesis of five different aryl-substituted glyoxylic acids in 89−92% 
yield after 3 h at room temperature (Scheme 63). 
 
Scheme 63. Synthesis of -keto acids fluorous selenic acid as catalyst 
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Table 13. Some selected -keto acids synthesized by Crich and coworkers [135] 














In 2016, Shibuya et al. reported the synthesis of -keto esters from -hydroxy acids using 2-
azaadamantane N-oxyl (AZADO), a nitroxyl radical catalyst [136]. This was a promising 
approach and highly atom-economical which does not require deprotection and hydrolysis 
(Scheme 64). A broad range of -hydroxy acids were efficiently oxidized to provide the 
corresponding -keto acids in high yield (Table 14). 
 
Scheme 64. Synthesis of -keto acids using AZADO as a catalyst 
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Table 14. Some -keto acids synthesized by Furukawa et al. [136] 

















3.1.3 -keto acids as acylating agents 
In 1991, Fontana and coworkers [137] reported for the first time the use of -keto acids as 
acylating agents in the selective acylation of heteroaromatic bases 94−96. A silver-catalyzed 
oxidative decarboxylation of -keto acids by (NH4)2S2O8 in a biphasic system (H2O/CH2Cl2) or 





Scheme 65. Silver catalyzed acylation of heteroaromatic bases using -keto acids 
In 2008, Gooen and coworkers reported synthesis of unsymmetrical ketones using -keto 
acids by direct acylation of aromatic rings [138]. Twenty-six differently substituted 
unsymmetrical ketones 102 were prepared in 5−99% yields after 16−36 h of reaction at 170 °C, 
by the cross-coupling reaction of -keto acid potassium salts 100 and aryl bromides 101. The 
reaction was catalyzed by Cu/Pd, in the presence of P-(o-Tol)3 and 1,10-phenanthroline as ligands 
and using a mixture of NMP/quinoline (3:1) as the solvent (Scheme 66). 
 
Scheme 66. Pd/Cu-catalyzed decarboxylative cross-coupling 
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Table 15. Selected examples of direct acylation using -keto acids [138] 



























Chen and coworkers [139] have developed an interesting way to prepare ynones 103, 
ynamides 104, and ynoates 105, respectively, by the reaction of alkynes with -keto acids, 
carbamoyl keto acids, and alkoxycarbonyl keto acids. The authors have combined the use of 
photoredox catalysis with hypervalent iodine(III) reagents, i.e., Benziodoxole acetate (BI-OAc) 





Scheme 67. Hypervalent Iodine(III) and Ru(II)-Photocatalyzation of BI-alkyne 
The usefulness of this method was demonstrated in the synthesis of ynamide 104a (Fig. 43), 
which is an effective inhibitor for the metabotropic glutamate receptor 5 (mGlu5 receptor) with a 
therapeutic potential for both peripheral and CNS disorders [140]. 
 






3.2 Pyruvic acid 
Pyruvic acid also known as 2-oxopropanoic acid (80) is the simplest alpha-keto acid (Fig. 44). 
It plays a central role in energy metabolism in living organisms. It is widely used in drug, 
agrochemical, chemical and food industries. Some applications of pyruvic acid include 
significantly increasing fat and weight loss [141], improving exercise endurance capacity [142], 
effectively reducing cholesterol [143], serving as a potent antioxidant [144],  and reducing anoxic 
injury and free radical generation [145]. Pyruvate, the conjugate base, CH3COCOO
−, is a key 
intermediate in several metabolic pathways throughout the cell. 
 
Fig. 44. Pyruvic acid 
3.2.1 Chemical syntheses of pyruvic acid 
In 1932, Howland and Fraser developed a method for the synthesis of pyruvic acid on an 
industrial scale [146]. In this process, pyruvic acid is distilled from a mixture of tartaric acid and 
potassium hydrogen sulfates at 220°C. The crude acid obtained is then distilled under vacuum. 





3.2.2 Biotechnological production of pyruvic acid 
Compared to the chemical method, production of pyruvic acid by using biotechnological 
methods is an alternative approach to reduce the production cost. There are three methods for 
biotechnological production of pyruvate: the direct fermentation method, the resting cell method, 
and the enzymatic method. Of these, direct fermentative production of pyruvate from a carbon 
source (such as glucose) has merits in terms of both cost-effectiveness and the high purity of the 
product. However, as pyruvate is located at a vital junction of cell metabolism, it is usually 
difficult to obtain strains that can accumulate large amounts of pyruvate extracellularly. 
In 1989, researchers in Toray industries, Japan, identifiede some yeast strains belonging to the 
genus Tirulopsis, that produced more than 50 g/l pyruvate [147]. This result indicated that the 
fermentative production of pyruvate can be commercialized. Pyruvate production using the 
fermentative method, with a scale of about 400 tons per year, was industrialized by Toray 
Industries in 1992 and the fermentation has now been scaled-up to 50 m3 fermentors [148]. 
3.3 Pyruvate esters 
Pyruvate is a three-carbon (triose) ketoacid (107, Fig. 45) that is produced in biological 
systems in the end stages of glycolysis, a product of sugar metabolism. It is also a breakdown 
product of certain amino acids (alanine, glycine, cysteine, Serine). Pyruvate can be reduced to 
lactate in the cytoplasm, a fermentative event in mammalian cells, or oxidatively decarboxylated 
to acetyl CoA in the mitochondrion [149]. It has been suggested that pyruvate and certain pyruvate 
derivatives may have utility in treating certain disorders and promoting health. For example, 
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pyruvate is sold as a dietary supplement for use in promoting weight loss and enhancing energy. 
It has also been suggested as a therapeutic intervention for clinical management of myocardial 
insufficiency [150] and to prevent the adverse effects of myocardial ischemia [151].  
 
Fig. 45 General formula for pyruvate  
U.S. Pat. No. 6,086,789 describes certain pyruvate derivatives as useful for dermatologic 
indications as well as for treating diabetic ketosis, myocardial ischemia, injured organs and 
hypercholesterolemia. Specifically, it ascribes these activities to various esters of pyruvate, 
including polyol-pyruvate esters, pyruvate thioesters, glycerol pyruvate esters, and 
dihydroxyacetone-pyruvate ester (Fig. 46). Related U.S. Pat. No. 5,968,727 describes the use of 
pyruvate thioesters, such as cysteine, methionine and homocysteine, and glycerol pyruvate esters 
and dihydroxyacetone-pyruvate esters, in organ preservation solutions and for treating ischemia. 
Similarly, certain pyruvate and pyruvyl amino acid conjugates have been suggested for use in 





Fig. 46. Some biologically active pyruvate esters 
U.S. Pat. No. 5,283,260, describes the treatment of diabetes with a physiologically acceptable 
form of pyruvate. The patent discloses a pyruvate compound in the form of a covalently linked 
pyruvyl-amino acid. However, administration of large amounts of pyruvate-amino acid may result 
in nitrogen overload which could harm patients with liver and/or kidney pathology. 
Notwithstanding the acceptance of pyruvate as an effective component of a reperfusion solution 
or other varied applications, pyruvic acid is a strong and unstable acid which cannot be infused as 
such. Furthermore, it has been recognized that traditional pharmacological pyruvate compounds, 
such as salts of pyruvic acid, are not particularly physiologically suitable. For example, these com 
pounds lead to the accumulation of large concentrations of ions (calcium or sodium) in the patient's 
body fluids. Similarly, amino acid compounds containing pyruvate can lead to excessive nitrogen 




3.3.1 Preparation of ethyl pyruvate: Recent developments 
Pyruvate (107), is an effective scavenger of reactive oxygen species (ROS) and has been 
shown to be salutary in numerous models of redox-mediated tissue or organ injury. However, it is 
unstable in solution and, hence, not attractive for development as a therapeutic agent. Pyruvate 
esters like ethyl pyruvate are thought to be more stable and has been reported to mitigate the 
damage caused by various stressors, such as, hemorrhagic shock, stroke, sepsis, and acute 
pancreatitis [155] [156] [157] [158]. Preparation of pyruvate esters directly from pyruvic acid has 
proven to be difficult. Pyruvic acid easily undergoes decarboxylation to give acetic acid (108) and 
carbon dioxide (Scheme 68). Therefore, an alternate approach must be taken for preparation of 
these esters. 
 
Scheme 68. Decarboxylation of pyruvic acid 
Currently, the commercial production of pyruvate esters is realized by the dehydrative 
decarboxylation of tartaric acid. Excess KHSO4 as a dehydrating agent is required in this process, 
leading to low atom efficiency and environmental pollution [159]. Thus, the development of a 
green, efficient, alternative route for the production of pyruvate is necessary. In 2018, Zhou et al. 
reported a highly efficient oxidation of ethyl lactate (109) to ethyl pyruvate (110) in the presence 
of TS-1 catalyst (a Titanium-substituted zeolite) and aqueous 30% hydrogen peroxide (H2O2) 
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[160]. The reaction was carried out under mild conditions without any solvent (Scheme 69). At 
50 ℃, 109 can be completely oxidized to 110 with ≥95% yield. However, the prolongation of 
reaction time and higher temperature led to the hydrolysis and eventual decarboxylation of 110. 
 
Scheme 69. Oxidation of ethyl lactate to ethyl pyruvate 
In the same year, Shiju et al. reported the direct oxidative dehydrogenation of lactates with 
molecular oxygen is a “greener” alternative for producing pyruvate esters [161]. The authors 
reported a one-pot synthesis of mesoporous vanadia−titania (Meso-VTN), acting as highly 
efficient and recyclable catalysts for the conversion of ethyl lactate to ethyl pyruvate (Scheme 
70). Mesoporous vanadia−titania nanocrystals (meso-VTN) were synthesized via the coassembly 
of vanadium and titanium precursors in the presence of an amphiphilic triblock copolymer as a 





Scheme 70. Oxidative dehydrogenation of ethyl lactate to ethyl pyruvate 
3.3.2 Biological applications of ethyl pyruvate 
Ethyl pyruvate was originally regarded as simply a way to administer pyruvate anion, whilst 
avoiding some of the problems associated with the instability of pyruvate in aqueous solutions. 
Increasingly, however, it is becoming apparent that certain pyruvate esters, including ethyl 
pyruvate, have pharmacological effects, such as suppression of inflammation, that are quite 
distinct from those exerted by pyruvate anion. 
Sims et al. found that treatment with ethyl pyruvate restores much of the structural and 
functional damage to the intestinal mucosa that normally occurs when rats are subjected to 
mesenteric ischemia/reperfusion [162]. Treatment with ethyl pyruvate seemed to be more 
effective than treatment with an equimolar dose of sodium pyruvate. Similar findings indicating 
that ethyl pyruvate is more effective than pyruvate, were reported by Varma et al.., who compared 
the two compounds an in vitro study of redox-mediated cellular injury [163]. 
Sepsis, a lethal syndrome that develops in response to infection, occurs in 750,000 patients per 
year in the United States and is fatal in 20–40% of cases [164] [165]. It is mediated by an early 
(e.g., tumor necrosis factor) and late [e.g., high mobility group B-1 (HMGB1)] proinflammatory 
cytokine response to infection. Fink and coworkers identified ethyl pyruvate, a stable lipophilic, 
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as an experimental therapeutic that effectively protects animals from ischemia/reperfusion-
induced tissue injury [166] [162]. Ethyl pyruvate administration significantly improved survival 
in standard models of lethal hemorrhagic shock [167]. The authors reported that ethyl pyruvate 
rescued animals from lethal sepsis caused by peritonitis, even when dosing began 24 h after cecal 
puncture. It inhibited the release of tumor necrosis factor and HMGB1 from endotoxin stimulated 
RAW 264.7 murine cell lines and attenuated activation of both the p38 mitogen-activated protein 
kinase (MAPK) and NF-B (nuclear factor kappa-light-chain-enhancer of activated B cells) 
signaling pathways. Ethyl pyruvate treatment of septic mice decreased circulating levels of 
HMGB1, indicating that delayed administration of ethyl pyruvate protects against lethal sepsis. 
In 2010, Muller and coworkers reported that ethyl pyruvate elicits a potent immune-based 
antitumor response through inhibition of indoleamine 2,3-dioxygenase (IDO), a key tolerogenic 
enzyme for many human tumors [168]. Consistent with its reported ability to interfere with NF-
κB function, ethyl pyruvate blocks IDO induction both in vitro and in vivo. The findings that IDO 
is effectively blocked by ethyl pyruvate treatment deepens emerging links between IDO and 
inflammatory processes. Furthermore, these findings rationalize oncologic applications for this 
agent by providing a compelling basis to reposition ethyl pyruvate as a low-cost 




3.4 Project rationale and design strategy 
As previously described, pyruvate esters have been increasingly of interest to the 
pharmaceutical industry. It can be used to treat various medical conditions and has proved to more 
effective than pyruvic acid itself. Simple esters like methyl pyruvate and ethyl pyruvate have been 
synthesized and studied in the past. However, the more complex esters of pyruvic acid have been 
difficult to develop. Therefore, it was of interest to develop a general synthesis of a series of 
pyruvate esters.  
Our group had previously developed a synthesis for glyceryl tripyruvate (111). The first step 
involved the synthesis of ethyl-4-substituted--methylcinnamate (112) using Horner-Wadsworth-
Emmons reaction [169] starting from 4-substituted-benzaldehyde (113) and 
(carbethoxyethylidene)triphenylphosphorane (114). The ethyl cinnamate 112 was then converted 
to the corresponding carboxylic acid (115) which was subsequently converted to 4-substituted--
methylcinnamoyl chloride (116) in quantitative yield using thionyl chloride. 116 was then 
converted to glyceryl tris(4-substituted--methylcinnamate) (117) in 61% yield by reacting 116 
with glycerol in pyridine. The triester 117 was converted to the tripyruvate (118) using ozonolysis 
chemistry in 89% yield. The tripyruvate 118 was isolated from the byproducts by liquid/liquid 
extraction. The tripyruvate (118) water solution was then freeze-dried to yield 118 in pure form 









Using similar synthetic procedures, a synthetic route for pyruvate esters was developed. The 
retrosynthetic route is illustrated in Scheme 72. Using Horner-Wadsworth-Emmons reaction, 
synthesis of ethyl 2,3-dimethylbut-2-enoate could be achieved from ethyl-2-
(diethoxyphospryl)propanoate and acetone. The ethyl ester can be hydrolyzed to the 
corresponding acid which can be converted to a series of esters using a coupling reagent like N-
(3-Dimethylaminopropyl)-N’-ethylcarbodiimide (EDCI). The esters can then undergo ozonolysis 
to give the corresponding pyruvates. 
 




RESULTS AND DISCUSSION 
3.5 Synthesis of ethyl 2,3-dimethyl-2-butenoate 
Ethyl 2,3-dimethyl-2-butenoate was prepared using Horner-Wadsworth-Emmons reaction. 
This method is used to synthesize olefins from phosphorus ylides (phosphonates) and 
aldehydes/ketones [170]. Ethyl 2,3-dimethyl-2-butenoate (118) was synthesized from triethyl-2-
phosphonopropionate (119) and acetone in the presence of a base. A general reaction scheme is 
illustrated in Scheme 73. 
 
Scheme 73. General scheme for synthesis of ethyl 2,3-dimethyl-2-butenoate 
 Bases like sodium hydride (NaH) and sodium ethoxide (NaOEt) were found to be suitable 
bases for this reaction. First, sodium metal was used to prepare NaOEt in situ with ethanol as the 
solvent. The reaction was run at room temperature under an inert atmosphere to give 118 as a 
colorless oil. The reaction conditions were optimized by varying the number of equivalents of 
sodium metal. However, the highest yield was only 32%. The reaction was repeated with 
purchased anhydrous NaOEt in various amounts which gave 118 in 21-32% yield.  
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Next, NaH was used as the base in THF. Varying the amount of acetone also affected the yield 
of the reaction. It was determined that using 3 equivalents of NaH and 1.5 equivalents of acetone 
were the best conditions for the reaction and gave 118 in 75% yield. 
 
Scheme 74. Optimized reaction scheme for synthesis of 118 
 




Table 16. Optimization of reaction conditions for synthesis of 118 
Entry Base Equivalents Solvent Acetone (equiv.) Yield of 118 (%) 
1 NaOEt 1 THF 1 21 
2 NaOEt 1.5 EtOH 1 23 
3 NaOEt 2 EtOH 1 23 
4 NaOEt 3 EtOH 1 30 
5 NaOEt 5 EtOH 1 32 
6 NaOEt 5 EtOH 3 30 
7 NaH 1 THF 1 56 
8 NaH 1.5 THF 1 55 
9 NaH 3 THF 1 60 






3.6 Synthesis of 2,3-dimethyl-2-butenoic acid 
The next step in the synthesis of pyruvate esters was to convert 118 to its corresponding 
carboxylic acid (120). This was achieved by base hydrolysis of 118. First, 3 equivalents of 
lithium hydroxide (LiOH) was used as the base (Scheme 76). The reaction was stirred at room 
temperature but there was no visible product formation by TLC. The reaction was then heated to 
50 ℃ which led to the formation of 120 in 52% yield.  
 
Scheme 76. Synthesis of 120 using LiOH 
 The reaction was repeated with 3 equivalents of sodium hydroxide (NaOH) as the base 
and EtOH as the solvent. NaOH was dissolved in minimum amount of water and was then added 
to the reaction mixture. The reaction was stirred overnight to give 120 in 57% yield. These 
conditions were optimized (Table 17) by heating the reaction mixture to reflux temperature. This 





Table 17. Reaction conditions for synthesis of 120 
Entry Base Solvent Temperature (℃) Yield of 120 (%) 
1 LiOH THF:H2O (1:1) 25 0 
2 LiOH THF:H2O (1:1) 50 52 
3 NaOH EtOH/H2O 25 57 
4 NaOH EtOH/H2O Reflux 99 
 
3.7 Synthesis of esters of 2,3-dimethyl-2-butenoic acid 
With the acid in hand, a series of esters were prepared using Steglich esterification [171]. The 
acid 120 was treated with benzyl alcohols (121a), 4-bromobenzyl alcohol (121b), ethylene glycol 
(121c) and neopentyl glycol (121d) (Fig. 47) in the presence of a carbodiimide coupling reagent 
(EDCI) and a suitable organic base N, N-dimethyl aminopyridine (DMAP) or N,N-diisopropyl 
ethylamine (DIPEA). The reaction conditions were optimized with benzyl alcohol (121a) 
(Scheme 77, Table 18). It was noted that using 3 equivalents of the alcohol and 5 equivalents of 




Fig. 47. Alcohols used to prepare the esters of 120 
 
Scheme 77. Synthesis of benzyl ester 125 
Table 18. Reaction condition optimization for synthesis of 122a 
Entry Equivalents of 121a Base Equivalents of base Yield of 122a (%) 
1 1 DMAP 1 46 
2 1.5 DMAP 2 45 
3 3 DMAP 3 50 
4 3 DIPEA 3 75 
5 3 DIPEA 5 86 
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The optimized conditions were then used to prepare esters 122a-f in 75-89% yield (Scheme 
78). It was observed that dialcohols like ethylene glycol and neopentyl alcohol produced the 
monoesters 122c and 122d. The monoesters were then used to repeat the esterification with the 
acid 120 to produce the diesters 122e and 122f (Fig. 48). 
 
Scheme 78. Synthesis of esters 122a-f 
 




Synthesis of diesters 122e and 122f is illustrated in scheme 79 and 80 below. 
 
Scheme 79. Synthesis of diester 122e 
 





Table 19. Optimized yields of esters 122a-f 
Entry ROH Yield of 122 (%) 
a 121a 86 
b 121b 89 
c 121c 75 
d 121d 78 
e 122c 76 
f 122d 78 
 
3.8 Synthesis pf pyruvate esters 
 Pyruvate esters were prepared by ozonolysis of the synthesized esters 122a-d. Ozolnolysis is 
a method to oxidatively cleave alkenes or alkynes with ozone (O3). The carbon-carbon double 
bond is replaced by a double bond with oxygen. The intermediate formed is an ozonide molecule 




Scheme 81. Ozonide formation during ozonolysis 
The ozonide intermediate is reduced with either triphenyl phosphine (PPh3) or dimethyl sulfide 
(DMS) to give the carbonyl compounds. Using this method, the esters 122a-b and 122e-f were 
treated with ozone at -78 ℃ in dichloromethane and then subsequently reduced with PPh3 to give 
the corresponding pyruvate esters 123a-d (Fig. 49) in moderate to high yields (56-93%) (Scheme 
82). The pyruvate esters were separated from the byproduct triphenyl phosphine oxide by column 
chromatography and obtained as colorless oils. 
 














In summary, a general synthesis for the preparation of pyruvate esters was developed. A series 
of alkyl pyruvate esters were synthesized in moderate to high yield in four steps. Horner-
Wadsworth-Emmons reaction was used to synthesize the alkene precursor which was converted 
to the corresponding ester and subsequently converted to pyruvate esters via ozonolysis. The 
reaction conditions can be applied to prepare both mono and diesters. Mono esters were isolated 







All reactions were carried out in oven-dried glassware under a N2 atmosphere unless otherwise 
noted. All chemicals were purchased from Alfa Aesar, Sigma Aldrich, and VWR and were used 
as received without further purification. Chromatography refers to flash silica gel column 
chromatography (0.060–0.200mm (60 Å) silica gel from Sorbent Technology was used as the 
stationary phase).  1H NMR and 13C NMR spectra were recorded at room temperature in DMSO-
d6 on a Bruker 300 MHz instrument.  
1H chemical shifts were referenced to the DMSO solvent 
signal (2.48 ppm). 13C chemical shifts were referenced to the DMSO solvent signal (40.00 ppm). 
Synthesis of ethyl 2,3-dimethyl-2-butenoate (118) 
Sodium hydride (6.05 g, 0.252 mol) was added to anhydrous THF (50 mL). The mixture was 
stirred at room temperature for 30 minutes under inert atmosphere. Triethyl-2-
phosphonopropionate (20.0 mL, 0.0840 mol) was added to the solution and stirred for an 
additional 30 minutes. Anhydrous acetone (9.26 mL, 0.126 mol) was then added to the reaction 
mixture and the reaction was stirred for 24 hours at room temperature. The reaction was diluted 
with water (50 mL) extracted with diethyl ether (3 x 50 mL). The organic layers were combined 
and washed with brine (100 mL) and dried over anhydrous sodium sulfate. The sodium sulfate 




1HNMR (DMSO-d6, 300 MHz) : 4.08 (q, J = 7.0 Hz, 2H), 1.92 (s, 3H), 1.79 – 1.72 (m, 6H), 1.19 
(t, J = 7.3 Hz, 3H). 
13C NMR (DMSO-d6, 75 MHz) : 168.5, 142.2, 137.6, 122.0, 59.5, 22.4, 22.0, 15.4, 14.1. 
Synthesis of 2,3-dimethyl-2-butenoic acid (120) 
Ethyl 2,3-dimethyl-2-butenoate (10.0 mL, 0.0703 mol) was dissolved in ethanol (30.0 mL). NaOH 
(8.44 g, 0.211 mol) was dissolved separately in water (20.0 mL) was added to the reaction mixture. 
The mixture was heated at reflux for 24 h. The reaction mixture was concentrated under vacuum 
and diluted with water (50 mL). The solution was made acidic to pH 2 by adding 3M HCl. The 
aqueous solution then was extracted with ethyl acetate (3 x 15 mL). The organic layers were 
combined and washed with brine (30 mL) and dried over anhydrous sodium sulfate. The sodium 
sulfate was filtered and the solvent was removed under vacuum to give a light-yellow oil. The oil 
was cooled to give light yellow crystals (8.00 g, 99% yield). mp 52.3-54.0 ℃ 
1H NMR (DMSO-d6, 300 MHz) : 12.07 (s, 1H), 1.92 (s, 3H), 1.74 (d, J = 3.6 Hz, 7H). 
13C NMR (DMSO-d6, 75 MHz) : 170.4, 141.3, 122.8, 22.5, 22.1, 15.6. 
Synthesis of 2,3-dimethyl-2-butenoate esters (122a-f) 
 
General procedure A 
2,3-dimethyl-2-butenoic acid (1 equivalent), alcohol (3 equivalents), and EDC•HCl (3 
equivalents) were dissolved in anhydrous DMF (20.0 mL). DIPEA (5 equivalents) was added to 
the reaction mixture and stirred under inert atmosphere for 24 h. The reaction was diluted with 
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water (100 mL) and extracted with ethyl acetate (3 x 20 mL). The organic layers were combined 
and washed with water (5 x 20 mL), brine (50 mL) and the dried over anhydrous sodium sulfate. 
The sodium sulfate was filtered and the solvent was removed under vacuum. The residue was 
purified by column chromatography (30% EtOAc:Hex) to give the esters 122a-d as colorless oils. 
Benzyl 2,3-dimethyl-2-butenoate (122a) 
General procedure A. Ester 122a was prepared using 120 (1.00 g, 8.76 mmol), alcohol 121a 
(2.72 mL, 26.3 mmol), EDC•HCl (4.08 26.3 mmol) and DIPEA (7.63 mL, 4.37 mmol) and was 
obtained as a colorless oil (1.60 g, 89% yield). 
1H NMR (DMSO-d6, 300MHz) : 7.35-7.30 (m, 5H), 5.12 (s, 2H), 1.93 (s, 3H), 1.80 (s, 3H), 1.75 
(s, 3H). 
13C NMR (DMSO-d6, 75 MHz) : 168.3, 143.5, 136.5, 128.4, 127.9, 121.7, 112.5, 65.3, 46.0, 
22.6, 15.4. 
4-bromobenzyl 2,3-dimethyl-2-butenoate (122b) 
General procedure A. Ester 122b was prepared using 120 (1.00 g, 8.76 mmol), alcohol 121a 
(2.72 mL, 26.3 mmol), EDC•HCl (4.08 26.3 mmol) and DIPEA (7.63 mL, 4.37 mmol) and was 
obtained as a colorless oil (2.21 g, 89% yield). 
1H NMR (DMSO-d6, 300 MHz) : 7.55 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.3 Hz, 2H), 5.09 (s, 2H), 
1.93 (s, 3H), 1.78 (d, J = 11.0 Hz, 6H). 
13CNMR (DMSO-d6, 75 MHz) : 168.3, 143.5, 136.5, 128.4, 127.9, 121.7, 112.5, 65.3, 22.6, 15.4. 
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2-hydroxyethyl 2,3-dimethylbut-2-enoate (122c) 
General procedure A. Mono ester 122e was prepared using 120 (1.00 g, 8.76 mmol), alcohol 
121a (2.72 mL, 26.3 mmol), EDC•HCl (4.08 26.3 mmol) and DIPEA (7.63 mL, 4.37 mmol) and 
was obtained as a colorless oil (1.04 g, 75% yield) 
1H NMR (DMSO-d6, 300 MHz) : 5.37 (s, 1H), 4.27 (t, J = 7.3 Hz, 2H), 3.8 (t, J = 7.3 Hz, 2H), 
2.37 (s, 3H), 2.21 (s, 3H), 1.92 (s, 3H).  
3-hydroxy-2,2-dimethylpropyl 2,3-dimethylbut-2-enoate (122d) 
General procedure A. Mono ester 122d was prepared using 120 (1.00 g, 8.76 mmol), alcohol 
121a (2.72 mL, 26.3 mmol), EDC•HCl (4.08 26.3 mmol) and DIPEA (7.63 mL, 4.37 mmol) and 
was obtained as a colorless oil (1.75 g, 78% yield). 
1H NMR (DMSO-d6, 300 MHz) : 4.60 (t, J = 5.4 Hz, 1H), 3.80 (s, 2H), 3.17 (d, J = 5.4 Hz, 2H), 
1.95 (d, J = 6.6 Hz, 3H), 1.83 – 1.72 (m, 6H), 0.83 (s, 6H). 
 
Ethane-1,2-diyl bis(2,3-dimethylbut-2-enoate) (122e) 
General procedure A. Diester 122e was prepared from 120 (0.120 g, 1.05 mmol), 122 c (0.500 
g, 3.16 mmol), EDC•HCl (0.490 g, 3.16 mmol) and DIPEA (1.00 mL, 5.25 mmol) and was 
obtained as a colorless oil (0.208g, 76% yield). 
1H NMR (DMSO-d6, 300 MHz) : 4.28 (s, 4H), 1.92 (s, 6H), 1.75 (s, 12H). 
13C NMR (DMSO-d6, 75 MHz) : 168.7, 144.0, 122.0, 112.9, 62.1, 23.0, 15.4. 
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2,2-dimethylpropane-1,3-diyl bis(2,3-dimethylbut-2-enoate) (122f) 
General procedure A. Diester 122f was prepared from 120 (0.200 g, 1.67 mmol), 122d (1.00 g, 
5.00 mmol), EDC•HCl (0.777 g, 5.00 mmol) and DIPEA (1.45 mL, 8.35 mmol) and was obtained 
as a colorless oil (0.390 g, 78% yield) 
1H NMR (DMSO-d6, 300 MHz) : 3.86 (s, 4H), 1.93 (s, 6H), 1.78-1.76 (m, 12H), 0.94 (s, 6H). 
Synthesis of pyruvate esters (123a-d) 
General procedure B 
The esters 122a-b and 122e-f were dissolved in anhydrous DCM (20.0 mL) and the reaction was 
cooled to -78 ℃. Ozone was bubbled through the solution until blue color persisted. Oxygen was 
then bubbled through until the blue color disappeared and solution turned colorless. Triphenyl 
phosphine (2 equivalents) was added to the reaction mixture and stirred at room temperature 
overnight. Water (20 mL) was added to the reaction mixture and the organic and aqueous layers 
were separated. The aqueous layer was extracted with DCM (3 x 15 mL). The organic layers were 
combined and washed with brine (20 mL) the organic layer was then dried over anhydrous sodium 
sulfate, filtered and the solvent was removed under vacuum. The residue was purified by column 
chromatography (50% EtOAc/Hex) to give the pyruvate esters 123a-d as colorless oils. 
Benzyl 2-oxopropanoate (123a) 
General procedure B. The pyruvate ester 123a was obtained from 122a (0.500 g, 2.45 mmol) as 
a colorless oil (0.406 g, 93% yield). 
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1H NMR (DMSO-d6, 300 MHz) : 7.41-7.35 (m, 5H), 5.22 (s, 2H), 2.38 (s, 3H). 
13C NMR (DMSO -d6, 75 MHz) : 191.6, 168.3, 143.5, 136.5, 128.4, 127.9, 65.3, 15.4. 
4-Bromobenzyl 2-oxopropanoate (123b) 
General procedure B. The pyruvate ester 123b was obtained from 122b (0.500 g, 1.76 mmol) as 
a colorless oil (0.400 g, 88% yield). 
1H NMR (DMSO-d6, 300 MHz) : 7.57 (d, J = 9Hz, 2H), 7.38 (d, J = 9Hz, 2H), 5.21 (s, 2H), 2.39 
(s, 3H). 
13C NMR (DMSO-d6, 75 MHz) : 191.6, 168.3, 136.5, 128.4, 127.9, 121.7, 112.6, 65.3, 22.6. 
Ethane-1,2-diyl bis(2-oxopropanoate) (123c) 
General procedure B. The pyruvate ester 123c was obtained from 122e (0.100 g, 0.400 mmol) 
as a colorless oil (0.0453 g, 56% yield). 
1H NMR (DMSO-d6, 300 MHz) : 4.44 (s, 4H), 2.36 (s, 6H). 
13C NMR (DMSO-d6, 75 MHz) : 191.6, 160.3, 63.6, 27.0. 
2,2-Dimethylpropane-1,3-diyl bis(2-oxopropanoate) (123d) 
General procedure B.  The pyruvate ester 123d was obtained from 122f (0.100 g, 0.337 mmol) 
as a colorless oil (0.0543 g, 66% yield). 
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1H NMR (DMSO-d6, 300 MHz) : 4.02 (s, 4H), 2.37 (s, 6H), 1.00 (s, 6H). 
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Crystal data for compound 23b 
 
Empirical formula C18H15Cl2O6S 
Formula weight 422.83 g mol-1 
Temperature 90 K 
Cu K radiation,  1.54184 Å 
Crystal system Orthorhombic, P212121 
Unit cell dimensions a = 4.793 (2) Å 
 b = 10.7214(5) Å  
 c = 35.1362 (15) Å 
Volume 1807.19 (14) Å3 
Z 4 
F (000) 872 
Density, Dx 1.554 Mg m-3 
Absorption coefficient,  3.32 mm-1 
Glancing angle,  − 
Crystal size 0.38 x 0.04 x 0.02 mm 






Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
 X y z Uiso*/Ueq 
Cl1 0.1699 (2) 0.18375 (15) 0.66169 (3) 0.0475 (4) 
S1 0.41916 (18) 0.93409 (8) 0.33766 (2) 0.0171 (2) 
O1 0.2404 (7) 0.5987 (3) 0.32286 (9) 0.0348 (8) 
O2 0.5969 (6) 0.9658 (3) 0.36869 (7) 0.0223 (6) 
O3 0.2181 (6) 1.0249 (3) 0.32606 (7) 0.0219 (6) 
O4 0.4988 (5) 0.6870 (3) 0.40902 (8) 0.0220 (6) 
O5 0.4861 (5) 0.4160 (2) 0.56660 (7) 0.0162 (5) 
O6 0.1861 (6) 0.2545 (3) 0.56434 (7) 0.0220 (6) 
N1 0.2633 (6) 0.7966 (3) 0.34577 (8) 0.0181 (7) 
N2 0.0749 (6) 0.6470 (3) 0.43556 (8) 0.0143 (6) 
H2N -0.092 (5) 0.663 (4) 0.4328 (12) 0.017* 
C1 0.3330 (8) 0.6971 (4) 0.32104 (10) 0.0221 (9) 
C2 0.5372 (7) 0.7492 (4) 0.29226 (10) 0.0178 (7) 
C3 0.5967 (7) 0.8740 (3) 0.29797 (10) 0.0156 (7) 
C4 0.7692 (7) 0.9412 (4) 0.27388 (10) 0.0178 (7) 
H4 0.8083 1.0269 0.2782 0.021* 
C5 0.8834 (8) 0.8772 (4) 0.24288 (10) 0.0219 (8) 
H5 1.0025 0.9200 0.2257 0.026* 
C6 0.8250 (9) 0.7530 (4) 0.23700 (10) 0.0236 (8) 
H6 0.9042 0.7113 0.2157 0.028* 
C7 0.6522 (8) 0.6875 (4) 0.26170 (11) 0.0228 (8) 
H7 0.6141 0.6016 0.2575 0.027* 
C8 0.0922 (8) 0.7755 (4) 0.37926 (10) 0.0212 (8) 
H8A -0.0812 0.7321 0.3716 0.025* 
H8B 0.0397 0.8569 0.3905 0.025* 
C9 0.2446 (7) 0.6973 (4) 0.40930 (10) 0.0154 (7) 
C10 0.1705 (7) 0.5830 (3) 0.46866 (9) 0.0135 (7) 
C11 0.0632 (8) 0.6143 (3) 0.50398 (10) 0.0174 (7) 
H11 -0.0777 0.6763 0.5058 0.021* 
C12 0.1598 (8) 0.5558 (4) 0.53683 (10) 0.0172 (7) 
H12 0.0855 0.5767 0.5611 0.021* 
C13 0.3664 (7) 0.4667 (3) 0.53331 (9) 0.0147 (7) 
C14 0.4713 (7) 0.4314 (4) 0.49841 (10) 0.0181 (7) 
H14 0.6092 0.3681 0.4967 0.022* 
C15 0.3729 (8) 0.4897 (3) 0.46556 (10) 0.0167 (7) 
H15 0.4428 0.4663 0.4413 0.020* 
C16 0.3845 (8) 0.3036 (3) 0.57833 (9) 0.0147 (7) 
C17 0.5638 (8) 0.2532 (4) 0.60987 (10) 0.0191 (8) 
H17A 0.7490 0.2314 0.5994 0.023* 
H17B 0.5914 0.3194 0.6291 0.023* 
C18 0.4432 (9) 0.1403 (4) 0.62901 (12) 0.0280 (9) 
H18A 0.5921 0.0958 0.6430 0.034* 
H18B 0.3672 0.0830 0.6095 0.034* 
 
 
Atomic displacement parameters (Å2) 
 
 U11 U22 U33 U12 U13 U23 
Cl1 0.0232 (5) 0.0896 (10) 0.0297 (5) -0.0022 (6) -0.0033 (4) 0.0278 (6) 




O1 0.0450 (19) 0.0235 (17) 0.0360 (17) -0.0023 (15) 0.0029 (15) 0.0060 (13) 
O2 0.0233 (13) 0.0289 (15) 0.0147 (12) 0.0032 (12) -0.0029 (11) -0.0020 (10) 
O3 0.0238 (14) 0.0206 (14) 0.0215 (13) 0.0067 (11) -0.0025 (11) 0.0007 (10) 
O4 0.0107 (13) 0.0298 (15) 0.0256 (13) 0.0024 (11) 0.0002 (10) 0.0100 (12) 
O5 0.0197 (12) 0.0161 (13) 0.0129 (11) -0.0005 (10) -0.0035 (9) 0.0038 (10) 
O6 0.0260 (14) 0.0201 (14) 0.0199 (13) -0.0068 (12) -0.0079 (11) 0.0039 (11) 
N1 0.0192 (14) 0.0203 (16) 0.0147 (15) -0.0016 (12) 0.0010 (12) 0.0055 (12) 
N2 0.0101 (13) 0.0184 (15) 0.0145 (14) 0.0020 (12) -0.0020 (12) 0.0027 (12) 
C1 0.0134 (17) 0.040 (3) 0.0127 (16) -0.0007 (17) -0.0042 (14) 0.0001 (16) 
C2 0.0179 (17) 0.0188 (18) 0.0169 (16) 0.0000 (15) -0.0043 (14) 0.0039 (15) 
C3 0.0165 (16) 0.0179 (18) 0.0125 (15) 0.0027 (15) -0.0020 (14) 0.0028 (13) 
C4 0.0204 (17) 0.0153 (17) 0.0179 (17) 0.0001 (15) -0.0026 (14) 0.0006 (15) 
C5 0.0210 (18) 0.030 (2) 0.0148 (17) 0.0024 (17) 0.0005 (15) 0.0031 (15) 
C6 0.0246 (19) 0.030 (2) 0.0161 (17) 0.0054 (18) 0.0011 (15) -0.0071 (16) 
C7 0.025 (2) 0.0182 (19) 0.0255 (19) -0.0003 (17) -0.0049 (16) -0.0052 (16) 
C8 0.0148 (17) 0.029 (2) 0.0199 (17) 0.0041 (16) 0.0033 (15) 0.0109 (16) 
C9 0.0157 (17) 0.0174 (18) 0.0132 (16) -0.0003 (14) -0.0009 (13) 0.0050 (14) 
C10 0.0117 (15) 0.0147 (17) 0.0142 (16) -0.0004 (13) -0.0008 (13) 0.0020 (13) 
C11 0.0182 (17) 0.0171 (17) 0.0169 (17) 0.0036 (15) 0.0009 (15) 0.0029 (14) 
C12 0.0200 (16) 0.0196 (18) 0.0119 (15) 0.0010 (15) 0.0029 (13) -0.0004 (14) 
C13 0.0164 (16) 0.0158 (18) 0.0120 (16) -0.0041 (13) -0.0043 (13) 0.0039 (13) 
C14 0.0197 (17) 0.0178 (18) 0.0167 (16) 0.0067 (15) -0.0011 (14) 0.0005 (15) 
C15 0.0208 (18) 0.0180 (18) 0.0115 (16) 0.0028 (15) 0.0020 (14) -0.0004 (13) 
C16 0.0197 (18) 0.0114 (16) 0.0131 (15) 0.0027 (15) 0.0018 (14) -0.0014 (13) 
C17 0.0190 (17) 0.0205 (19) 0.0180 (17) 0.0023 (17) -0.0041 (14) 0.0034 (15) 
C18 0.029 (2) 0.027 (2) 0.028 (2) -0.0016 (19) -0.0092 (18) 0.0103 (17) 
 
 
Geometric parameters (Å, )  
Cl1-C18 1.804 (5) C6-C7 1.390 (6) 
S1-O2 1.425 (3) C6-H6 0.9500 
S1-O3 1.430 (3) C7-H7 0.9500 
S1-N1 1.677 (3) C8-C9 1.534 (5) 
S1-C3 1.756 (4) C8-H8A 0.9900 
O1-C1 1.146 (5) C8-H8B 0.9900 
O4-C9 1.225 (4) C10-C11 1.384 (5) 
O5-C16 1.363 (4) C10-C15 1.398 (5) 
O5-C13 1.412 (4) C11-C12 1.393 (5) 
O6-C16 1.194 (5) C11-H11 0.9500 
N1-C1 1.416 (5) C12-C13 1.383 (5) 
N1-C8 1.452 (4) C12-H12 0.9500 
N2-C9 1.344 (5) C13-C14 1.378 (5) 
N2-C10 1.426 (4) C14-C15 1.395 (5) 
N2-H2N 0.82 (2) C14-H14 0.9500 
C1-C2 1.514 (5) C15-H15 0.9500 
C2-C7 1.376 (5) C16-C17 1.503 (5) 
C2-C3 1.384 (5) C17-C18 1.501 (6) 
C3-C4 1.386 (5) C17-H17A 0.9900 
C4-C5 1.399 (5) C17-H17B 0.9900 
C4-H4 0.9500 C18-H18A 0.9900 
C5-C6 1.377 (6) C18-H18B 0.9900 




O2-S1-O3 117.34 (17) C9-C8-H8B 109.2 
O2-S1-N1 110.26 (16) H8A-C8-H8B 107.9 
O3-S1-N1 110.25 (17) O4-C9-N2 124.9 (3) 
O2-S1-C3 113.88 (17) O4-C9-C8 121.2 (3) 
O3-S1-C3 110.51 (16) N2-C9-C8 113.8 (3) 
N1-S1-C3 91.65 (16) C11-C10-C15 120.1 (3) 
C16-O5-C13 116.5 (3) C11-C10-N2 119.7 (3) 
C1-N1-C8 120.9 (3) C15-C10-N2 120.2 (3) 
C1-N1-S1 116.9 (3) C10-C11-C12 120.7 (3) 
C8-N1-S1 121.8 (3) C10-C11-H11 119.7 
C9-N2-C10 123.9 (3) C12-C11-H11 119.7 
C9-N2-H2N 115 (3) C13-C12-C11 118.4 (3) 
C10-N2-H2N 120 (3) C13-C12-H12 120.8 
O1-C1-N1 124.6 (4) C11-C12-H12 120.8 
O1-C1-C2 128.8 (4) C14-C13-C12 122.1 (3) 
N1-C1-C2 106.5 (3) C14-C13-O5 118.9 (3) 
C7-C2-C3 119.7 (4) C12-C13-O5 118.9 (3) 
C7-C2-C1 127.1 (4) C13-C14-C15 119.3 (3) 
C3-C2-C1 113.2 (3) C13-C14-H14 120.3 
C2-C3-C4 122.5 (3) C15-C14-H14 120.3 
C2-C3-S1 111.7 (3) C14-C15-C10 119.4 (3) 
C4-C3-S1 125.7 (3) C14-C15-H15 120.3 
C3-C4-C5 117.0 (4) C10-C15-H15 120.3 
C3-C4-H4 121.5 O6-C16-O5 123.4 (3) 
C5-C4-H4 121.5 O6-C16-C17 127.0 (3) 
C6-C5-C4 120.8 (4) O5-C16-C17 109.6 (3) 
C6-C5-H5 119.6 C18-C17-C16 113.5 (3) 
C4-C5-H5 119.6 C18-C17-H17A 108.9 
C5-C6-C7 121.1 (4) C16-C17-H17A 108.9 
C5-C6-H6 119.5 C18-C17-H17B 108.9 
C7-C6-H6 119.5 C16-C17-H17B 108.9 
C2-C7-C6 118.9 (4) H17A-C17-H17B 107.7 
C2-C7-H7 120.5 C17-C18-Cl1 110.9 (3) 
C6-C7-H7 120.5 C17-C18-H18A 109.5 
N1-C8-C9 111.9 (3) Cl1-C18-H18A 109.5 
N1-C8-H8A 109.2 C17-C18-H18B 109.5 
C9-C8-H8A 109.2 Cl1-C18-H18B 109.5 
N1-C8-H8B 109.2 H18A-C18-H18B 108.0 
O2-S1-N1-C1 -114.8 (3) C3-C2-C7-C6 -0.4 (5) 
O3-S1-N1-C1 114.0 (3) C1-C2-C7-C6 176.5 (3) 
C3-S1-N1-C1 1.4 (3) C5-C6-C7-C2 0.5 (6) 
O2-S1-N1-C8 57.6 (3) C1-N1-C8-C9 68.3 (4) 
O3-S1-N1-C8 -73.5 (3) S1-N1-C8-C9 -103.8 (3) 
C3-S1-N1-C8 173.9 (3) C10-N2-C9-O4 5.5 (6) 
C8-N1-C1-O1 8.5 (6) C10-N2-C9-C8 -172.4 (3) 
S1-N1-C1-O1 -179.0 (3) N1-C8-C9-O4 19.2 (6) 
C8-N1-C1-C2 -173.7 (3) N1-C8-C9-N2 -162.7 (3) 
S1-N1-C1-C2 -1.2 (4) C9-N2-C10-C11 130.4 (4) 
O1-C1-C2-C7 0.7 (7) C9-N2-C10-C15 -49.2 (5) 




O1-C1-C2-C3 177.8 (4)  N2-C10-C11-C12  -178.0 (3) 
N1-C1-C2-C3 0.1 (4)  C10-C11-C12-C13  0.5 (6) 
C7-C2-C3-C4 0.2 (5)  C11-C12-C13-C14  -2.3 (6) 
C1-C2-C3-C4 -177.2 (3)  C11-C12-C13-O5  173.6 (3) 
C7-C2-C3-S1 178.2 (3)  C16-O5-C13-C14  -85.8 (4) 
C1-C2-C3-S1 0.8 (4)  C16-O5-C13-C12  98.2 (4) 
O2-S1-C3-C2 111.8 (3)  C12-C13-C14-C15  2.0 (6) 
O3-S1-C3-C2 -113.6 (3)  O5-C13-C14-C15  -173.9 (3) 
N1-S1-C3-C2 -1.3 (3)  C13-C14-C15-C10  0.2 (6) 
O2-S1-C3-C4 -70.3 (4)  C11-C10-C15-C14  -1.9 (6) 
O3-S1-C3-C4 64.3 (4)  N2-C10-C15-C14  177.6 (3) 
N1-S1-C3-C4 176.7 (3)  C13-O5-C16-O6  -7.8 (5) 
C2-C3-C4-C5 0.1 (5)  C13-O5-C16-C17  170.7 (3) 
S1-C3-C4-C5 -177.6 (3)  O6-C16-C17-C18  -11.0 (6) 
C3-C4-C5-C6 -0.1 (5)  O5-C16-C17-C18  170.6 (3) 
C4-C5-C6-C7 -0.2 (6)  C16-C17-C18-Cl1  -77.7 (4) 
 
Hydrogen-bond geometry (Å, ) 
     
D-H...A  D-H H...A D...A D-H...A 
N2-H2N...O4i  0.82 (2) 2.15 (3) 2.948 (4) 163 (4) 




Crystal structure data for compound 29 
 
Empirical formula C22H26ClNO11 
Formula weight 515.89 g mol-1 
Crystal system Triclinic, P1 
Unit cell dimensions a = 5.6938 (2) Å 
 b = 9.5493 (3) Å 
 c = 23.0194 (10) Å 
  = 80.255 (3) 
  = 84.336 (3) 
  = 74.482 (3) 
Volume  1186.04 (8) Å3  
Z 2 
F(000) 540 
Density, Dx 1.445 Mg m3  
Reflections 4969 
Cu K radiation,  1.54184 Å 
Absorption coefficient,  1.98 mm-1 
Glancing angle,  − 
Temperature 100 K 
Crystal appearance Lath, colorless 











Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
 
 x y z Uiso*/Ueq 
Cl1 -0.7062 (2) 1.00327 (13) 0.50527 (6) 0.0312 (3) 
O1 0.4826 (6) 0.6306 (4) 0.77619 (15) 0.0263 (8) 
O2 0.6996 (6) 0.3340 (4) 0.81977 (15) 0.0244 (7) 
O3 0.7625 (6) 0.2967 (4) 0.94607 (16) 0.0255 (7) 
O4 0.2796 (6) 0.4222 (4) 1.00594 (15) 0.0255 (7) 
O5 0.2860 (6) 0.6612 (4) 0.86546 (15) 0.0261 (8) 
O6 -0.1918 (7) 0.7809 (4) 0.92324 (16) 0.0310 (8) 
O7 1.0924 (7) 0.3215 (4) 0.83128 (19) 0.0372 (9) 
O8 0.5915 (7) 0.1134 (4) 0.98913 (18) 0.0365 (9) 
O9 0.5555 (8) 0.4408 (5) 1.06609 (18) 0.0418 (10) 
O10 -0.0614 (7) 0.9829 (4) 0.88502 (18) 0.0355 (9) 
O11 -0.3347 (7) 0.8003 (4) 0.57867 (16) 0.0314 (8) 
N1 -0.1986 (8) 0.9709 (4) 0.61503 (19) 0.0238 (9) 
H1N -0.190 (11) 1.059 (5) 0.612 (2) 0.029* 
C1 0.3965 (9) 0.5551 (5) 0.8286 (2) 0.0232 (10) 
H1 0.2763 0.5031 0.8198 0.028* 
C2 0.6153 (9) 0.4463 (5) 0.8574 (2) 0.0233 (10) 
H2 0.7466 0.4963 0.8600 0.028* 
C3 0.5412 (9) 0.3774 (5) 0.9182 (2) 0.0232 (10) 
H3 0.4418 0.3079 0.9142 0.028* 
C4 0.3936 (9) 0.4927 (5) 0.9549 (2) 0.0234 (10) 
H4 0.5002 0.5495 0.9669 0.028* 
C5 0.1851 (9) 0.5953 (5) 0.9195 (2) 0.0256 (11) 
H5 0.0763 0.5366 0.9100 0.031* 
C6 0.0363 (10) 0.7155 (6) 0.9522 (2) 0.0334 (13) 
H6A 0.0029 0.6747 0.9938 0.040* 
H6B 0.1268 0.7910 0.9517 0.040* 
C7 0.9415 (10) 0.2832 (5) 0.8091 (2) 0.0285 (11) 
C8 0.9947 (11) 0.1763 (6) 0.7659 (3) 0.0342 (12) 
H8A 1.0625 0.2201 0.7285 0.051* 
H8B 0.8434 0.1528 0.7590 0.051* 
H8C 1.1129 0.0861 0.7819 0.051* 
C9 0.7644 (10) 0.1653 (6) 0.9804 (2) 0.0273 (11) 
C10 1.0094 (11) 0.0966 (6) 1.0043 (3) 0.0378 (13) 
H10A 1.0060 0.0045 1.0305 0.057* 
H10B 1.0525 0.1640 1.0266 0.057* 
H10C 1.1311 0.0761 0.9716 0.057* 
C11 0.3745 (10) 0.4047 (5) 1.0592 (2) 0.0282 (11) 
C12 0.2280 (11) 0.3298 (6) 1.1066 (2) 0.0350 (13) 
H12A 0.3028 0.2236 1.1126 0.053* 
H12B 0.0607 0.3487 1.0945 0.053* 
H12C 0.2252 0.3683 1.1436 0.053* 
C13 -0.2142 (10) 0.9146 (6) 0.8899 (2) 0.0313 (12) 
C14 -0.4503 (11) 0.9640 (6) 0.8605 (3) 0.0393 (14) 
H14A -0.5842 0.9550 0.8899 0.059* 
H14B -0.4471 0.9026 0.8303 0.059* 
H14C -0.4750 1.0669 0.8419 0.059* 
C15 0.3047 (9) 0.7108 (5) 0.7371 (2) 0.0240 (10) 




H16 0.1104 0.5595 0.7403 0.034* 
C17 -0.0459 (10) 0.7371 (5) 0.6821 (2) 0.0252 (10) 
H17 -0.1717 0.6983 0.6724 0.030* 
C18 -0.0291 (9) 0.8783 (5) 0.6554 (2) 0.0218 (10) 
C19 0.1549 (10) 0.9332 (6) 0.6707 (2) 0.0272 (11) 
H19 0.1674 1.0285 0.6528 0.033* 
C20 0.3199 (9) 0.8513 (5) 0.7114 (2) 0.0261 (11) 
H20 0.4435 0.8908 0.7219 0.031* 
C21 -0.3351 (10) 0.9285 (5) 0.5801 (2) 0.0245 (10) 
C22 -0.4925 (10) 1.0582 (5) 0.5416 (2) 0.0289 (11) 
H22A -0.3866 1.1038 0.5117 0.035* 
H22B -0.5809 1.1330 0.5663 0.035* 
Cl2 -0.5533 (2) 0.31244 (14) 0.66050 (6) 0.0367 (3) 
O12 0.7046 (6) 0.5089 (4) 0.40215 (15) 0.0272 (8) 
O13 0.7343 (6) 0.7914 (4) 0.35463 (15) 0.0258 (8) 
O14 0.8760 (6) 0.8247 (4) 0.22857 (15) 0.0258 (8) 
O15 0.5657 (6) 0.6921 (4) 0.16795 (15) 0.0276 (8) 
O16 0.6617 (7) 0.4608 (4) 0.31063 (15) 0.0285 (8) 
O17 0.3916 (7) 0.3178 (4) 0.25014 (17) 0.0342 (9) 
O18 1.1230 (7) 0.8094 (4) 0.34078 (18) 0.0356 (9) 
O19 0.5747 (7) 1.0042 (4) 0.18398 (18) 0.0381 (9) 
O20 0.9071 (7) 0.6781 (5) 0.10762 (17) 0.0382 (9) 
O21 0.6816 (8) 0.1321 (4) 0.29495 (18) 0.0400 (10) 
O22 -0.0867 (7) 0.2630 (4) 0.58902 (16) 0.0315 (9) 
N2 -0.0767 (8) 0.5040 (5) 0.56905 (19) 0.0261 (9) 
H2N -0.135 (10) 0.587 (5) 0.579 (3) 0.031* 
C23 0.6287 (9) 0.5742 (5) 0.3455 (2) 0.0242 (10) 
H23 0.4528 0.6294 0.3478 0.029* 
C24 0.7832 (10) 0.6774 (5) 0.3180 (2) 0.0247 (10) 
H24 0.9603 0.6243 0.3172 0.030* 
C25 0.7040 (9) 0.7436 (5) 0.2559 (2) 0.0237 (10) 
H25 0.5370 0.8117 0.2579 0.028* 
C26 0.7032 (10) 0.6248 (6) 0.2199 (2) 0.0251 (11) 
H26 0.8734 0.5714 0.2085 0.030* 
C27 0.5622 (10) 0.5181 (6) 0.2542 (2) 0.0289 (11) 
H27 0.3869 0.5718 0.2599 0.035* 
C28 0.5779 (11) 0.3896 (6) 0.2232 (2) 0.0355 (13) 
H28A 0.5516 0.4238 0.1807 0.043* 
H28B 0.7414 0.3201 0.2271 0.043* 
C29 0.9255 (10) 0.8414 (6) 0.3653 (2) 0.0283 (11) 
C30 0.8543 (11) 0.9361 (6) 0.4127 (3) 0.0366 (13) 
H30A 0.8860 0.8750 0.4513 0.055* 
H30B 0.6801 0.9863 0.4113 0.055* 
H30C 0.9500 1.0094 0.4065 0.055* 
C31 0.7857 (10) 0.9558 (5) 0.1942 (2) 0.0274 (11) 
C32 0.9889 (11) 1.0265 (6) 0.1720 (3) 0.0368 (13) 
H32A 0.9264 1.1162 0.1442 0.055* 
H32B 1.1176 0.9582 0.1518 0.055* 
H32C 1.0559 1.0515 0.2053 0.055* 
C33 0.6862 (10) 0.7126 (6) 0.1150 (2) 0.0270 (11) 
C34 0.5109 (10) 0.7885 (6) 0.0689 (2) 0.0326 (12) 




H34B 0.3541 0.7642 0.0799 0.049* 
H34C 0.5753 0.7564 0.0310 0.049* 
C35 0.4721 (11) 0.1927 (6) 0.2877 (3) 0.0352 (13) 
C36 0.2583 (11) 0.1405 (7) 0.3189 (3) 0.0394 (14) 
H36A 0.3184 0.0488 0.3458 0.059* 
H36B 0.1591 0.1233 0.2897 0.059* 
H36C 0.1587 0.2155 0.3416 0.059* 
C37 0.5096 (9) 0.5037 (5) 0.4437 (2) 0.0240 (10) 
C38 0.3782 (10) 0.4004 (5) 0.4462 (2) 0.0261 (11) 
H38 0.4220 0.3304 0.4197 0.031* 
C39 0.1826 (9) 0.3980 (5) 0.4870 (2) 0.0271 (11) 
H39 0.0902 0.3282 0.4879 0.033* 
C40 0.1229 (9) 0.4987 (5) 0.5267 (2) 0.0239 (10) 
C41 0.2536 (10) 0.6036 (6) 0.5240 (2) 0.0291 (11) 
H41 0.2101 0.6735 0.5505 0.035* 
C42 0.4495 (10) 0.6065 (6) 0.4822 (2) 0.0275 (11) 
H42 0.5399 0.6777 0.4803 0.033* 
C43 -0.1665 (9) 0.3916 (5) 0.5971 (2) 0.0252 (11) 
C44 -0.3681 (10) 0.4395 (6) 0.6425 (3) 0.0308 (12) 
H44A -0.4713 0.5375 0.6270 0.037* 
H44B -0.2961 0.4483 0.6787 0.037* 
 
 
Atomic displacement parameters (Å2) 
 
 U11 U22 U33 U12 U13 U23 
Cl1 0.0314 (7) 0.0264 (6) 0.0369 (7) -0.0049 (5) -0.0084 (5) -0.0080 (5) 
O1 0.0244 (19) 0.0255 (18) 0.0278 (19) -0.0068 (15) -0.0015 (14) -0.0004 (14) 
O2 0.0250 (18) 0.0207 (17) 0.0271 (18) -0.0029 (14) 0.0000 (14) -0.0080 (14) 
O3 0.0206 (18) 0.0226 (17) 0.0320 (19) -0.0024 (14) -0.0057 (14) -0.0029 (14) 
O4 0.0256 (18) 0.0283 (18) 0.0231 (18) -0.0073 (15) -0.0020 (14) -0.0041 (14) 
O5 0.028 (2) 0.0201 (17) 0.0264 (19) -0.0002 (15) -0.0004 (14) -0.0031 (14) 
O6 0.026 (2) 0.0266 (19) 0.036 (2) -0.0023 (16) 0.0013 (16) -0.0025 (15) 
O7 0.024 (2) 0.030 (2) 0.059 (3) -0.0093 (17) 0.0035 (18) -0.0127 (18) 
O8 0.030 (2) 0.031 (2) 0.046 (2) -0.0104 (17) -0.0003 (17) 0.0034 (17) 
O9 0.048 (3) 0.051 (3) 0.035 (2) -0.029 (2) -0.0115 (19) 0.0006 (19) 
O10 0.033 (2) 0.034 (2) 0.042 (2) -0.0132 (18) -0.0041 (17) -0.0035 (17) 
O11 0.043 (2) 0.0182 (18) 0.035 (2) -0.0059 (16) -0.0099 (17) -0.0059 (14) 
N1 0.025 (2) 0.016 (2) 0.031 (2) -0.0063 (18) -0.0074 (18) -0.0009 (17) 
C1 0.020 (2) 0.019 (2) 0.029 (3) -0.0005 (19) -0.0006 (19) -0.0077 (19) 
C2 0.026 (3) 0.015 (2) 0.030 (3) -0.004 (2) -0.002 (2) -0.0078 (19) 
C3 0.017 (2) 0.023 (3) 0.028 (3) -0.001 (2) -0.0051 (19) -0.005 (2) 
C4 0.022 (3) 0.023 (2) 0.024 (3) -0.004 (2) -0.0004 (19) -0.0037 (19) 
C5 0.023 (3) 0.025 (3) 0.026 (3) -0.002 (2) 0.000 (2) -0.004 (2) 
C6 0.030 (3) 0.032 (3) 0.033 (3) 0.003 (2) -0.005 (2) -0.006 (2) 
C7 0.032 (3) 0.019 (2) 0.030 (3) -0.006 (2) -0.001 (2) 0.004 (2) 
C8 0.035 (3) 0.031 (3) 0.035 (3) -0.006 (2) 0.005 (2) -0.007 (2) 
C9 0.031 (3) 0.024 (3) 0.026 (3) -0.004 (2) -0.005 (2) -0.004 (2) 
C10 0.037 (3) 0.034 (3) 0.039 (3) 0.001 (3) -0.016 (3) -0.002 (2) 
C11 0.037 (3) 0.021 (2) 0.028 (3) -0.007 (2) -0.007 (2) -0.004 (2) 
C12 0.038 (3) 0.034 (3) 0.032 (3) -0.011 (3) 0.000 (2) 0.001 (2) 
C13 0.032 (3) 0.027 (3) 0.032 (3) -0.001 (2) -0.001 (2) -0.008 (2) 




C15 0.026 (3) 0.020 (2) 0.023 (3) -0.001 (2) -0.003 (2) -0.0014 (19) 
C16 0.033 (3) 0.018 (2) 0.034 (3) -0.006 (2) -0.005 (2) -0.004 (2) 
C17 0.029 (3) 0.022 (3) 0.026 (3) -0.008 (2) -0.003 (2) -0.003 (2) 
C18 0.022 (3) 0.018 (2) 0.024 (2) -0.001 (2) -0.0015 (19) -0.0054 (18) 
C19 0.030 (3) 0.023 (3) 0.031 (3) -0.008 (2) -0.003 (2) -0.006 (2) 
C20 0.026 (3) 0.022 (3) 0.033 (3) -0.010 (2) -0.001 (2) -0.005 (2) 
C21 0.031 (3) 0.019 (2) 0.022 (2) -0.004 (2) -0.001 (2) -0.0038 (18) 
C22 0.035 (3) 0.019 (2) 0.032 (3) 0.000 (2) -0.012 (2) -0.008 (2) 
Cl2 0.0351 (7) 0.0325 (7) 0.0451 (8) -0.0143 (6) 0.0095 (6) -0.0101 (6) 
O12 0.0262 (19) 0.0301 (19) 0.0247 (19) -0.0078 (15) -0.0007 (14) -0.0015 (14) 
O13 0.0211 (18) 0.0265 (18) 0.033 (2) -0.0087 (15) -0.0023 (14) -0.0099 (15) 
O14 0.0259 (19) 0.0236 (18) 0.0302 (19) -0.0122 (15) -0.0003 (15) -0.0018 (14) 
O15 0.0284 (19) 0.0315 (19) 0.0255 (19) -0.0115 (16) -0.0007 (15) -0.0054 (15) 
O16 0.038 (2) 0.0242 (18) 0.0272 (19) -0.0135 (16) -0.0027 (15) -0.0048 (14) 
O17 0.040 (2) 0.033 (2) 0.034 (2) -0.0158 (18) -0.0082 (17) -0.0023 (16) 
O18 0.026 (2) 0.029 (2) 0.054 (3) -0.0076 (16) -0.0023 (18) -0.0102 (18) 
O19 0.038 (2) 0.029 (2) 0.046 (2) -0.0095 (18) -0.0080 (18) 0.0017 (17) 
O20 0.030 (2) 0.047 (2) 0.032 (2) -0.0057 (19) 0.0036 (16) -0.0028 (17) 
O21 0.041 (3) 0.036 (2) 0.045 (2) -0.0137 (19) -0.0050 (19) -0.0042 (18) 
O22 0.036 (2) 0.0209 (19) 0.036 (2) -0.0077 (16) 0.0056 (16) -0.0044 (15) 
N2 0.029 (2) 0.016 (2) 0.034 (2) -0.0068 (18) 0.0015 (18) -0.0061 (17) 
C23 0.027 (3) 0.022 (2) 0.025 (3) -0.007 (2) -0.001 (2) -0.0050 (19) 
C24 0.030 (3) 0.022 (2) 0.025 (3) -0.011 (2) 0.000 (2) -0.005 (2) 
C25 0.019 (3) 0.025 (3) 0.028 (3) -0.008 (2) 0.001 (2) -0.004 (2) 
C26 0.029 (3) 0.029 (3) 0.020 (2) -0.014 (2) 0.000 (2) -0.003 (2) 
C27 0.033 (3) 0.032 (3) 0.025 (3) -0.018 (2) 0.002 (2) -0.003 (2) 
C28 0.048 (4) 0.036 (3) 0.031 (3) -0.026 (3) 0.002 (2) -0.005 (2) 
C29 0.027 (3) 0.028 (3) 0.032 (3) -0.011 (2) -0.007 (2) -0.001 (2) 
C30 0.044 (4) 0.039 (3) 0.034 (3) -0.020 (3) -0.004 (3) -0.009 (2) 
C31 0.032 (3) 0.023 (3) 0.028 (3) -0.008 (2) -0.002 (2) -0.005 (2) 
C32 0.042 (3) 0.029 (3) 0.042 (3) -0.016 (3) 0.008 (3) -0.007 (2) 
C33 0.027 (3) 0.027 (3) 0.027 (3) -0.007 (2) 0.004 (2) -0.008 (2) 
C34 0.031 (3) 0.036 (3) 0.031 (3) -0.009 (2) -0.002 (2) -0.006 (2) 
C35 0.041 (4) 0.033 (3) 0.033 (3) -0.009 (3) -0.008 (3) -0.005 (2) 
C36 0.036 (3) 0.037 (3) 0.050 (4) -0.020 (3) -0.005 (3) -0.001 (3) 
C37 0.024 (3) 0.019 (2) 0.024 (3) -0.002 (2) -0.001 (2) 0.0025 (19) 
C38 0.033 (3) 0.020 (2) 0.024 (3) -0.005 (2) -0.001 (2) -0.0041 (19) 
C39 0.029 (3) 0.021 (2) 0.033 (3) -0.008 (2) -0.002 (2) -0.006 (2) 
C40 0.026 (3) 0.014 (2) 0.028 (3) -0.0010 (19) -0.001 (2) -0.0008 (18) 
C41 0.035 (3) 0.024 (3) 0.029 (3) -0.006 (2) -0.003 (2) -0.006 (2) 
C42 0.033 (3) 0.024 (3) 0.027 (3) -0.012 (2) -0.001 (2) -0.001 (2) 
C43 0.030 (3) 0.018 (2) 0.028 (3) -0.008 (2) -0.004 (2) -0.0040 (19) 




Geometric parameters (Å, )  
Cl1-C22 1.774 (5) Cl2-C44 1.783 (5) 
O1-C15 1.396 (6) O12-C37 1.397 (6) 
O1-C1 1.409 (6) O12-C23 1.401 (6) 
O2-C7 1.345 (6) O13-C29 1.359 (6) 
O2-C2 1.448 (5) O13-C24 1.443 (6) 




O3-C3 1.437 (6) O14-C25 1.439 (6) 
O4-C11 1.355 (6) O15-C33 1.349 (6) 
O4-C4 1.437 (6) O15-C26 1.451 (6) 
O5-C1 1.412 (5) O16-C23 1.420 (6) 
O5-C5 1.434 (6) O16-C27 1.430 (6) 
O6-C13 1.352 (7) O17-C35 1.347 (7) 
O6-C6 1.453 (6) O17-C28 1.446 (6) 
O7-C7 1.205 (7) O18-C29 1.195 (7) 
O8-C9 1.201 (7) O19-C31 1.197 (7) 
O9-C11 1.203 (7) O20-C33 1.214 (6) 
O10-C13 1.206 (7) O21-C35 1.193 (7) 
O11-C21 1.230 (6) O22-C43 1.230 (6) 
N1-C21 1.348 (6) N2-C43 1.348 (6) 
N1-C18 1.419 (6) N2-C40 1.419 (6) 
N1-H1N 0.85 (4) N2-H2N 0.84 (4) 
C1-C2 1.518 (7) C23-C24 1.511 (6) 
C1-H1 1.0000 C23-H23 1.0000 
C2-C3 1.510 (7) C24-C25 1.520 (7) 
C2-H2 1.0000 C24-H24 1.0000 
C3-C4 1.523 (6) C25-C26 1.517 (7) 
C3-H3 1.0000 C25-H25 1.0000 
C4-C5 1.526 (6) C26-C27 1.530 (7) 
C4-H4 1.0000 C26-H26 1.0000 
C5-C6 1.501 (7) C27-C28 1.500 (7) 
C5-H5 1.0000 C27-H27 1.0000 
C6-H6A 0.9900 C28-H28A 0.9900 
C6-H6B 0.9900 C28-H28B 0.9900 
C7-C8 1.500 (7) C29-C30 1.493 (7) 
C8-H8A 0.9800 C30-H30A 0.9800 
C8-H8B 0.9800 C30-H30B 0.9800 
C8-H8C 0.9800 C30-H30C 0.9800 
C9-C10 1.489 (7) C31-C32 1.496 (7) 
C10-H10A 0.9800 C32-H32A 0.9800 
C10-H10B 0.9800 C32-H32B 0.9800 
C10-H10C 0.9800 C32-H32C 0.9800 
C11-C12 1.506 (7) C33-C34 1.484 (7) 
C12-H12A 0.9800 C34-H34A 0.9800 
C12-H12B 0.9800 C34-H34B 0.9800 
C12-H12C 0.9800 C34-H34C 0.9800 
C13-C14 1.490 (8) C35-C36 1.508 (8) 
C14-H14A 0.9800 C36-H36A 0.9800 
C14-H14B 0.9800 C36-H36B 0.9800 
C14-H14C 0.9800 C36-H36C 0.9800 
C15-C16 1.384 (7) C37-C38 1.379 (7) 
C15-C20 1.391 (7) C37-C42 1.389 (7) 
C16-C17 1.381 (7) C38-C39 1.387 (7) 
C16-H16 0.9500 C38-H38 0.9500 
C17-C18 1.406 (7) C39-C40 1.394 (7) 
C17-H17 0.9500 C39-H39 0.9500 
C18-C19 1.388 (7) C40-C41 1.389 (7) 
C19-C20 1.379 (7) C41-C42 1.402 (7) 




C20-H20 0.9500 C42-H42 0.9500 
C21-C22 1.519 (7) C43-C44 1.505 (7) 
C22-H22A 0.9900 C44-H44A 0.9900 
C22-H22B 0.9900 C44-H44B 0.9900 
C15-O1-C1 115.7 (4) C37-O12-C23 112.8 (4) 
C7-O2-C2 118.3 (4) C29-O13-C24 117.5 (4) 
C9-O3-C3 118.0 (4) C31-O14-C25 117.3 (4) 
C11-O4-C4 118.9 (4) C33-O15-C26 119.4 (4) 
C1-O5-C5 111.2 (4) C23-O16-C27 110.9 (4) 
C13-O6-C6 116.8 (4) C35-O17-C28 115.3 (5) 
C21-N1-C18 127.0 (4) C43-N2-C40 128.0 (4) 
C21-N1-H1N 123 (4) C43-N2-H2N 118 (4) 
C18-N1-H1N 110 (4) C40-N2-H2N 114 (4) 
O1-C1-O5 107.0 (4) O12-C23-O16 108.0 (4) 
O1-C1-C2 107.8 (4) O12-C23-C24 109.8 (4) 
O5-C1-C2 110.0 (4) O16-C23-C24 109.0 (4) 
O1-C1-H1 110.7 O12-C23-H23 110.0 
O5-C1-H1 110.7 O16-C23-H23 110.0 
C2-C1-H1 110.7 C24-C23-H23 110.0 
O2-C2-C3 109.5 (4) O13-C24-C23 105.7 (4) 
O2-C2-C1 105.9 (4) O13-C24-C25 109.9 (4) 
C3-C2-C1 110.5 (4) C23-C24-C25 109.2 (4) 
O2-C2-H2 110.3 O13-C24-H24 110.7 
C3-C2-H2 110.3 C23-C24-H24 110.7 
C1-C2-H2 110.3 C25-C24-H24 110.7 
O3-C3-C2 106.8 (4) O14-C25-C26 109.5 (4) 
O3-C3-C4 110.3 (4) O14-C25-C24 107.2 (4) 
C2-C3-C4 111.9 (4) C26-C25-C24 111.2 (4) 
O3-C3-H3 109.3 O14-C25-H25 109.6 
C2-C3-H3 109.3 C26-C25-H25 109.6 
C4-C3-H3 109.3 C24-C25-H25 109.6 
O4-C4-C3 109.5 (4) O15-C26-C25 108.7 (4) 
O4-C4-C5 105.7 (4) O15-C26-C27 104.7 (4) 
C3-C4-C5 109.4 (4) C25-C26-C27 110.4 (4) 
O4-C4-H4 110.7 O15-C26-H26 110.9 
C3-C4-H4 110.7 C25-C26-H26 110.9 
C5-C4-H4 110.7 C27-C26-H26 110.9 
O5-C5-C6 108.5 (4) O16-C27-C28 107.4 (4) 
O5-C5-C4 108.7 (4) O16-C27-C26 109.5 (4) 
C6-C5-C4 112.5 (4) C28-C27-C26 112.4 (4) 
O5-C5-H5 109.0 O16-C27-H27 109.2 
C6-C5-H5 109.0 C28-C27-H27 109.2 
C4-C5-H5 109.0 C26-C27-H27 109.2 
O6-C6-C5 108.3 (4) O17-C28-C27 107.9 (4) 
O6-C6-H6A 110.0 O17-C28-H28A 110.1 
C5-C6-H6A 110.0 C27-C28-H28A 110.1 
O6-C6-H6B 110.0 O17-C28-H28B 110.1 
C5-C6-H6B 110.0 C27-C28-H28B 110.1 
H6A-C6-H6B 108.4 H28A-C28-H28B 108.4 
O7-C7-O2 123.5 (5) O18-C29-O13 123.7 (5) 




O2-C7-C8 111.0 (5) O13-C29-C30 110.4 (5) 
C7-C8-H8A 109.5 C29-C30-H30A 109.5 
C7-C8-H8B 109.5 C29-C30-H30B 109.5 
H8A-C8-H8B 109.5 H30A-C30-H30B 109.5 
C7-C8-H8C 109.5 C29-C30-H30C 109.5 
H8A-C8-H8C 109.5 H30A-C30-H30C 109.5 
H8B-C8-H8C 109.5 H30B-C30-H30C 109.5 
O8-C9-O3 123.9 (5) O19-C31-O14 123.9 (5) 
O8-C9-C10 125.8 (5) O19-C31-C32 126.5 (5) 
O3-C9-C10 110.3 (4) O14-C31-C32 109.6 (5) 
C9-C10-H10A 109.5 C31-C32-H32A 109.5 
C9-C10-H10B 109.5 C31-C32-H32B 109.5 
H10A-C10-H10B 109.5 H32A-C32-H32B 109.5 
C9-C10-H10C 109.5 C31-C32-H32C 109.5 
H10A-C10-H10C 109.5 H32A-C32-H32C 109.5 
H10B-C10-H10C 109.5 H32B-C32-H32C 109.5 
O9-C11-O4 123.5 (5) O20-C33-O15 123.8 (5) 
O9-C11-C12 125.9 (5) O20-C33-C34 126.0 (5) 
O4-C11-C12 110.5 (4) O15-C33-C34 110.2 (4) 
C11-C12-H12A 109.5 C33-C34-H34A 109.5 
C11-C12-H12B 109.5 C33-C34-H34B 109.5 
H12A-C12-H12B 109.5 H34A-C34-H34B 109.5 
C11-C12-H12C 109.5 C33-C34-H34C 109.5 
H12A-C12-H12C 109.5 H34A-C34-H34C 109.5 
H12B-C12-H12C 109.5 H34B-C34-H34C 109.5 
O10-C13-O6 123.8 (5) O21-C35-O17 124.9 (6) 
O10-C13-C14 125.3 (5) O21-C35-C36 125.1 (5) 
O6-C13-C14 110.8 (5) O17-C35-C36 110.0 (5) 
C13-C14-H14A 109.5 C35-C36-H36A 109.5 
C13-C14-H14B 109.5 C35-C36-H36B 109.5 
H14A-C14-H14B 109.5 H36A-C36-H36B 109.5 
C13-C14-H14C 109.5 C35-C36-H36C 109.5 
H14A-C14-H14C 109.5 H36A-C36-H36C 109.5 
H14B-C14-H14C 109.5 H36B-C36-H36C 109.5 
C16-C15-C20 119.9 (5) C38-C37-C42 120.6 (5) 
C16-C15-O1 122.8 (4) C38-C37-O12 121.2 (4) 
C20-C15-O1 117.3 (4) C42-C37-O12 118.2 (4) 
C17-C16-C15 120.6 (5) C37-C38-C39 120.6 (5) 
C17-C16-H16 119.7 C37-C38-H38 119.7 
C15-C16-H16 119.7 C39-C38-H38 119.7 
C16-C17-C18 119.7 (5) C38-C39-C40 119.4 (5) 
C16-C17-H17 120.1 C38-C39-H39 120.3 
C18-C17-H17 120.1 C40-C39-H39 120.3 
C19-C18-C17 119.1 (5) C41-C40-C39 120.1 (5) 
C19-C18-N1 117.9 (4) C41-C40-N2 117.2 (4) 
C17-C18-N1 122.9 (4) C39-C40-N2 122.5 (4) 
C20-C19-C18 120.9 (5) C40-C41-C42 120.1 (5) 
C20-C19-H19 119.5 C40-C41-H41 119.9 
C18-C19-H19 119.5 C42-C41-H41 119.9 
C19-C20-C15 119.8 (5) C37-C42-C41 119.1 (5) 
C19-C20-H20 120.1 C37-C42-H42 120.5 




O11-C21-N1 124.9 (5) O22-C43-N2 124.5 (5) 
O11-C21-C22 122.8 (4) O22-C43-C44 123.1 (5) 
N1-C21-C22 112.3 (4) N2-C43-C44 112.3 (4) 
C21-C22-Cl1 111.5 (4) C43-C44-Cl2 111.7 (4) 
C21-C22-H22A 109.3 C43-C44-H44A 109.3 
Cl1-C22-H22A 109.3 Cl2-C44-H44A 109.3 
C21-C22-H22B 109.3 C43-C44-H44B 109.3 
Cl1-C22-H22B 109.3 Cl2-C44-H44B 109.3 
H22A-C22-H22B 108.0 H44A-C44-H44B 107.9 
C15-O1-C1-O5 -75.7 (5) C37-O12-C23-O16 -104.4 (4) 
C15-O1-C1-C2 166.1 (4) C37-O12-C23-C24 136.9 (4) 
C5-O5-C1-O1 178.1 (4) C27-O16-C23-O12 173.4 (4) 
C5-O5-C1-C2 -65.1 (5) C27-O16-C23-C24 -67.3 (5) 
C7-O2-C2-C3 -102.3 (5) C29-O13-C24-C23 140.7 (4) 
C7-O2-C2-C1 138.5 (4) C29-O13-C24-C25 -101.6 (5) 
O1-C1-C2-O2 -69.8 (5) O12-C23-C24-O13 -63.7 (5) 
O5-C1-C2-O2 174.0 (4) O16-C23-C24-O13 178.3 (4) 
O1-C1-C2-C3 171.7 (4) O12-C23-C24-C25 178.2 (4) 
O5-C1-C2-C3 55.5 (5) O16-C23-C24-C25 60.1 (5) 
C9-O3-C3-C2 -141.7 (4) C31-O14-C25-C26 99.1 (5) 
C9-O3-C3-C4 96.6 (5) C31-O14-C25-C24 -140.2 (4) 
O2-C2-C3-O3 73.5 (4) O13-C24-C25-O14 72.2 (5) 
C1-C2-C3-O3 -170.2 (4) C23-C24-C25-O14 -172.4 (4) 
O2-C2-C3-C4 -165.8 (4) O13-C24-C25-C26 -168.2 (4) 
C1-C2-C3-C4 -49.5 (5) C23-C24-C25-C26 -52.7 (5) 
C11-O4-C4-C3 104.1 (5) C33-O15-C26-C25 104.0 (5) 
C11-O4-C4-C5 -138.0 (4) C33-O15-C26-C27 -138.0 (4) 
O3-C3-C4-O4 -74.9 (5) O14-C25-C26-O15 -77.1 (5) 
C2-C3-C4-O4 166.4 (4) C24-C25-C26-O15 164.6 (4) 
O3-C3-C4-C5 169.6 (4) O14-C25-C26-C27 168.6 (4) 
C2-C3-C4-C5 50.9 (5) C24-C25-C26-C27 50.3 (6) 
C1-O5-C5-C6 -170.9 (4) C23-O16-C27-C28 -173.4 (4) 
C1-O5-C5-C4 66.4 (5) C23-O16-C27-C26 64.3 (5) 
O4-C4-C5-O5 -175.6 (4) O15-C26-C27-O16 -171.7 (4) 
C3-C4-C5-O5 -57.7 (5) C25-C26-C27-O16 -54.8 (6) 
O4-C4-C5-C6 64.1 (5) O15-C26-C27-C28 69.1 (6) 
C3-C4-C5-C6 -178.0 (5) C25-C26-C27-C28 -174.1 (5) 
C13-O6-C6-C5 -105.1 (5) C35-O17-C28-C27 -102.8 (5) 
O5-C5-C6-O6 75.3 (5) O16-C27-C28-O17 74.3 (6) 
C4-C5-C6-O6 -164.4 (4) C26-C27-C28-O17 -165.2 (4) 
C2-O2-C7-O7 3.3 (7) C24-O13-C29-O18 9.2 (7) 
C2-O2-C7-C8 -175.8 (4) C24-O13-C29-C30 -169.0 (4) 
C3-O3-C9-O8 -0.6 (7) C25-O14-C31-O19 -2.6 (7) 
C3-O3-C9-C10 178.7 (4) C25-O14-C31-C32 177.6 (4) 
C4-O4-C11-O9 -2.6 (7) C26-O15-C33-O20 -0.2 (7) 
C4-O4-C11-C12 179.6 (4) C26-O15-C33-C34 -177.6 (4) 
C6-O6-C13-O10 -2.9 (7) C28-O17-C35-O21 -7.9 (8) 
C6-O6-C13-C14 176.9 (4) C28-O17-C35-C36 172.2 (4) 
C1-O1-C15-C16 -45.2 (6) C23-O12-C37-C38 77.4 (6) 
C1-O1-C15-C20 136.2 (5) C23-O12-C37-C42 -102.0 (5) 







O1-C15-C16-C17 -178.0 (4)  O12-C37-C38-C39  -179.0 (5) 
C15-C16-C17-C18 0.3 (8)  C37-C38-C39-C40  -1.6 (8) 
C16-C17-C18-C19 -0.6 (7)  C38-C39-C40-C41  2.0 (8) 
C16-C17-C18-N1 -177.9 (5)  C38-C39-C40-N2  179.1 (5) 
C21-N1-C18-C19 156.5 (5)  C43-N2-C40-C41  -150.7 (5) 
C21-N1-C18-C17 -26.2 (8)  C43-N2-C40-C39  32.2 (8) 
C17-C18-C19-C20 0.0 (7)  C39-C40-C41-C42  -1.4 (8) 
N1-C18-C19-C20 177.4 (4)  N2-C40-C41-C42  -178.6 (5) 
C18-C19-C20-C15 1.0 (8)  C38-C37-C42-C41  0.2 (8) 
C16-C15-C20-C19 -1.3 (8)  O12-C37-C42-C41  179.7 (4) 
O1-C15-C20-C19 177.4 (4)  C40-C41-C42-C37  0.2 (8) 
C18-N1-C21-O11 1.0 (9)  C40-N2-C43-O22  -1.0 (8) 
C18-N1-C21-C22 -178.8 (5)  C40-N2-C43-C44  175.6 (5) 
O11-C21-C22-Cl1 10.0 (7)  O22-C43-C44-Cl2  -23.5 (7) 
N1-C21-C22-Cl1 -170.3 (4)  N2-C43-C44-Cl2  159.8 (4) 
 
Hydrogen-bond geometry (Å, ) 
     
D-H...A  D-H H...A D...A D-H...A 
N1-H1N...O22i  0.85 (4) 2.15 (5) 2.973 (5) 165 (5) 
N2-H2N...O11  0.84 (4) 2.05 (5) 2.854 (5) 161 (6) 
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